Supplemental Table 1: Summary of identified manuscripts (n=515)

First author, year	Assayed Samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Included studies: Retrospective/prospective cohort studies meeting all eligibility requirements (n=37)						
Rangel J, 2008	-	345	-	Osteopontin	*Cancer* **112**: 144-150 (2008)	(1)
Pearl RA, 2008	-	76	92	MCAM	*J Plast Reconstr Aesthet Surg* **61**: 265-271 (2008)	(2)
Vaisanen AH, 2008	-	157	-	MMP-2, MMP-9	*Hum Pathol* **39**: 377-385 (2008) (epub Jan. 2008)	(3)
Alonso SR, 2007	-	127	-	Glypican-3, N-cadherin, osteonectin, osteopontin, protein kinase C-α	*Cancer Res* **67**: 3450-3460 (2007)	(4)
Piras F, 2007	-	50	-	Survivin	*Histopathology* **50**: 835-842 (2007)	(5)
Weinlich G, 2007	-	158	-	Metallothionein	*J Eur Acad Dermatol Venerol* **21**: 669-677 (2007)	(6)
Ekmekcioglu S, 2006	-	132	-	iNOS	*Int J Cancer* **119**: 861-866 (2006)	(7)
Pacifico MD, 2006	-	84	-	CD44v3	*Int J Cancer* **118**: 1460-1464 (2006)	(8)
Rangel J, 2006	-	343	-	NCOA3/AIB-1	*J Clin Oncol* **24**: 4565-4569 (2006)	(9)
Weinlich G, 2006	-	1270	-	Metallothionein	*Br J Cancer* **94**: 835-841 (2006)	(10)
Berger AJ, 2005	62	236	324	AP-2α	*Cancer Res* **65**: 11185-11192 (2005)	(11)
Pacifico MD, 2005a	-	76	-	P-cadherin	*Ann Plast Surg* **55**: 316-320 (2005)	(12)
Pacifico MD, 2005b	-	76	-	nm23	*Melanoma Res* **15**: 435-440 (2005)	(13)
Pacifico MD, 2005c	-	76	-	MCAM	*Plast Reconstr Surg* **115**: 367-375 (2005)	(14)
Scala S, 2005	-	71	-	CXCR4	*Clin Cancer Res* **11**: 1835-1841 (2005)	(15)
Soltani MH, 2005	-	37	-	Microtubule-associated protein-2	*Am J Pathol* **166**: 1841-1850 (2005)	(16)
Straume O, 2005	-	125	-	Ets-1, Id1	*Br J Cancer* **93**: 933-938 (2005)	(17)
Alonso SR, 2004	-	60	-	Bcl-2, bcl-6, bcl-xL, BMI-1, caveolin, cdk-1, cdk-2, cdk-6, c-Kit, cyclin A, cyclin B1, cyclin D1, cyclin D3, cyclin E, gp100, HDM2, IRF4/mum-1, Ki-67, Mel-18, MelanA, MHC Class II, MLH-1, p16/INK4A, p21/WAF1, p27/KIP1, p53, PH1, protein kinase Cβ, Rb, RING-1B, RYBP, Skp2, STAT-1, survivin, topoisomerase II	*Am J Pathol* **164**: 193-203 (2004)	(18)
Berger AJ, 2004	-	203	190	HDM2	*Cancer Res* **64**: 8767-8772 (2004)	(19)
Divito KA, 2004	-	269	233	Bcl-2	*Cancer Res* **64**: 8773-8777 (2004)	(20)
Hofbauer GF, 2004	-	91	-	gp100, MAGE-3, MelanA, MHC Class I, tyrosinase	*J Immunother* **27**: 73-78 (2004)	(21)
Ilmonen S, 2004	-	98	-	Tenascin-C	*Histopathology* **45**: 405-411(2004)	(22)
Li Q, 2004	22	119	35	p27/KIP1, Skp2	*J Cutan Pathol* **31**: 633-642 (2004)	(23)
Berger AJ, 2003	-	269	273	ATF-2	*Cancer Res* **63**: 8103-8107 (2003)	(24)
Korabiowska M, 2002a	19	76	31	Ku70, Ku80	*Mod Pathol* **15**: 426-433 (2002)	(25)
Thies A, 2002a	12	100	14	LI-CAM	*Eur J Cancer* **38**: 1708-1716 (2002)	(26)
Thies A, 2002b	-	100	18	CEACAM	*J Clin Oncol* **20**: 2530-2536 (2002)	(27)
Florenes VA, 2001	10	172	73	Cyclin A, Ki-67	*J Pathol* **195**: 530-536 (2001)	(28)
Ferrier CM, 2000	-	214	-	PAI-1, PAI-2, tPA, uPA, uPAR	*Br J Cancer* **83**: 1351-1359 (2000)	(29)
Florenes VA, 2000	10	172	73	Cyclin D1, cyclin D3	*Clin Cancer Res* **6**: 3614-3620 (2000)	(30)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Included studies: Retrospective/prospective cohort studies meeting all eligibility requirements (n=37), cont'd						
Karjalainen JM, 2000	-	282	-	CD44	*Am J Pathol* **157**: 957-965 (2000)	(31)
McDermott NC, 2000	-	157	-	nm23	*J Pathol* **190**: 157-162 (2000)	(32)
Straume O, 2000	-	187	68	Ki-67, p16/INK4a, p53	*Clin Cancer Res* **6**: 1845-1853 (2000)	(33)
Niezabitowski A, 1999	-	93	-	gp100, Ki-67, p53, PCNA, S100B, vimentin	*J Surg Oncol* **70**: 150-160 (1999)	(34)
Karjalainen JM, 1998	-	273	-	AP-2α	*J Clin Oncol* **16**: 3584-3591 (1998)	(35)
Tran TA, 1998	60	66	-	Cyclin A, cyclin B, cdk-1, Ki-67	*Hum Pathol* **29**: 1085-1090 (1998)	(36)
Vaisanen AH, 1998	-	50	0	MMP-2	*J Pathol* **186**: 51-58 (1998)	(37)
Excluded studies: Retrospective/prospective cohort studies with data redundant with another cohort study study (n=4)						
Potti A, 2003b	-	202	-	VEGF	*Anticancer Res* **23**: 4023-4026 (2003)	(38)
Potti A, 2003c	-	202	-	c-Kit, Her2/neu	*J Carcinog* **2**: 8 (2003)	(39)
Weinlich G, 2003	-	520	-	Metallothionein	*Br J Dermatol* **149**: 535-541 (20030	(40)
Straume O, 1997	-	187	-	Ki-67, p53	*Int J Cancer* **74**: 535-539 (1997)	(41)
Excluded studies: Retrospective/prospective cohort studies that did not sample primary melanomas (n=1)						
Vlaykova T, 2002	-	-	60	Bcl-2	*Oncology* **62**: 259-268 (2002)	(42)
Excluded studies: Retrospective/prospective cohort studies that did not report risk estimate or associated confidence intervals (n=12)						
Pearl RA, 2007	-	79	82	Ki-67	*J Exp Clin Cancer Res* **26**: 109-115 (2007)	(43)
Mihic-Probst D, 2006	34	64	-	p16/INK4A	*Int J Cancer* **118**: 2262-2268 (2006)	(44)
Potti A, 2004	-	202	-	c-Kit, Her2/neu, VEGF	*J Cancer Res Clin Oncol* **130**: 80-86 (2004)	(45)
Giatromanolaki A, 2003	-	46	-	HIF-1α, HIF-2α, thymidine phosphorylase, VEGF	*Melanoma Res* **13**: 493-501 (2003)	(46)
Maelandsmo GM, 2003	7	164	66	β-catenin	*Clin Cancer Res* **9**: 3383-3388 (2003)	(47)
Mu XC, 2000	63	117	46	Topoisomerase II	*J Cutan Pathol* **27**: 242-248 (2000)	(48)
Hieken TJ, 1999	-	111	-	Integrin β1, integrin β3, p53	*Cancer* **85**: 375-382 (1999)	(49)
Karjalainen JM, 1999	-	284	-	p21/WAF1, p53, PCNA	*Br J Cancer* **79**: 895-902 (1999)	(50)
Ostmeier H, 1999	-	691	-	Integrin α2, ICAM-1, L-selectin, MHC Class I, MHC Class II	*Cancer* **85**: 2391-2399	(51)
Talve LA, 1996a	-	76	-	Ki-67	*J Cutan Pathol* **23**: 335-343 (1996)	(52)
Talve LA, 1996b	-	80	-	p53	*Pathol Res Pract* **192**: 825-833 (1996)	(53)
Ramsay JA, 1995a	-	64	-	Ki-67	*J Invest Dermatol* **105**: 22-26 (1995)	(54)
Excluded studies: Retrospective/prospective cohort studies reporting only univariate risk estimates (n=21)						
McCarthy MM, 2008	540	230	293	HSP90	*Ann Oncol* **19**: 590-594 (2008) (epub Nov. 2007)	(55)
Jorgensen K, 2006	27	154	73	JNK, p38 MAPK	*Mod Pathol* **19**: 1446-1455 (2006)	(56)
Lu F, 2006	68	79	43	ING2	*Br J Cancer* **95**: 80-86 (2006)	(57)
McCarthy MM, 2006	540	203	314	TRAIL-R1, TRAIL-R2	*Clin Cancer Res* **12**: 3856-3863 (2006)	(58)
Sirigu P, 2006	-	82	-	p16/INK4A, p53	*Eur J Histochem* **50**: 191-198 (2006)	(59)
Slipicevic A, 2005	41	162	71	Akt, PTEN	*Am J Clin Pathol* **124**: 528-536 (2005)	(60)
Zhuang L, 2005	20	42	38	ERK 1/2	*J Clin Pathol* **58**: 1163-1169 (2005)	(61)
Andersen K, 2004	8	159	62	E-cadherin, S100A4	*Mod Pathol* **17**: 990-997 (2004)	(62)
Bachmann IM, 2004	-	160	59	Cyclin D1, cdk4, p14/ARF, Rb	*Int J Oncol* **25**: 1559-1565 (2004)	(63)
Dai DL, 2004	13	70	-	APAF-1	*Br J Cancer* **91**: 1089-1095 (2004)	(64)
Florenes VA, 2004	8	152	64	$p75^{NTR}$, Trk-A	*Am J Clin Pathol* **122**: 412-420 (2004)	(65)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Retrospective/prospective cohort studies reporting only univariate risk estimates (n=21), cont'd						
Korabiowska M, 2004a	36	88	28	APC	*Mod Pathol* **17**: 1539-1544 (2004)	(66)
Torlakovic EE, 2004	23	69	28	Ets-1	*Mod Pathol* **17**: 1400-1406 (2004)	(67)
Cruz J, 2003	-	59	-	c-Met	*Oncology* **65**: 72-82 (2003)	(68)
Jorgensen K, 2003	41	172	67	ERK 1/2	*Clin Cancer Res* **9**: 5325-5331 (2003)	(69)
Korabiowska M, 2002	-	106	-	GADD34, GADD45, GADD153	*Histol Histopathol* **17**: 805-811 (2002)	(70)
Nikkola J, 2002	-	-	56	MMP-1, MMP-3, MMP-13	*Int J Cancer* **97**: 432-438 (2002)	(71)
Straume O, 2002	-	176	56	EphA2, Ephrin A1, FGFR1, FGF-2, IL-8, VEGF-type C, FLT-4	*Am J Pathol* **160**: 1009-1019 (2002)	(72)
Straume O, 2001	-	187	68	Thrombospondin-1, VEGF, FLT-1, FLK	*Am J Pathol* **159**: 223-235 (2001)	(73)
Ekmekcioglu S, 2000	-	-	20	iNOS	*Clin Cancer Res* **6**: 4768-4775 (2000)	(74)
Henrique R, 2000	-	82	-	Ki-67	*J Am Acad Dermatol* **43**: 991-1000 (2000)	(75)
Excluded studies: Retrospective/prospective cohort studies reporting incomplete immunohistochemistry methods (n=27)						
Dai DL, 2008	52	159	52	Bim	*J Invest Dermatol* **128**: 403-407 (2008) (epub July 2007)	(76)
Tucci MG, 2007	-	30	-	β-catenin, CXCR4, E-cadherin, cdc42	*Br J Dermatol* **157**: 1212-1216 (2007)	(77)
Wang Y, 2007	58	114	50	ING3	*Clin Cancer Res* **13**: 4111-4115 (2007)	(78)
Bachmann IM, 2006	-	202	58	EZH2	*J Clin Oncol* **24**: 268-273 (2006)	(79)
Streit S, 2006	-	137	-	FGFR4	*Br J Cancer* **94**: 1879-1886 (2006)	(80)
Bachmann IM, 2005	31	149	58	β-catenin, E-cadherin, Frizzled, N-cadherin, P-cadherin, wnt-5α	*Clin Cancer Res* **11**: 8606-8614 (2005)	(81)
Dai DL, 2005	70	170	52	Akt	*J Clin Oncol* **23**: 1473-1482 (2005)	(82)
Gimotty PA, 2005	-	396	-	Ki-67	*J Clin Oncol* **23**: 8048-8056 (2005)	(83)
Ilmonen S, 2005a	-	113	-	Bcl-2, Ki-67, p53	*Melanoma Res* **15**: 375-381 (2005)	(84)
Ilmonen S, 2005b	-	95	12	Ezrin	*Mod Pathol* **18**: 503-510 (2005)	(85)
Karst AM, 2005	64	107	51	PUMA	*Oncogene* **24**: 1111-1116 (2005)	(86)
Staibano S, 2005	15	80	-	PARP-1	*Hum Pathol* **36**: 724-731 (2005)	(87)
Zhou Y, 2005	35	85	18	Osteopontin	*J Invest Dermatol* **124**: 1044-1052 (2005)	(88)
Korabiowska, 2004b	-	109	-	Cytokeratin 8	*Anticancer Res* **24**: 3203-3207 (2004)	(89)
Nikkola J, 2004	-	-	68	Integrin αv, Integrin β1	*Melanoma Res* **14**: 29-37 (2004)	(90)
Dai DL, 2003	12	76	-	Integrin-linked kinase	*Clin Cancer Res* **9**: 4409-4414 (2003)	(91)
Kielhorn E, 2003	-	75	80	β-catenin	*Int J Cancer* **103**: 652-656 (2003)	(92)
Gutman M, 2002	-	49	57	IL-8	*Anticancer Res* **22**: 3395-3398 (2002)	(93)
Hazan C, 2002	-	137	-	Ki-67	*Cancer* **95**: 634-640 (2002)	(94)
Polsky D, 2002	-	134	-	HDM2, p53	*J Natl Cancer Inst* **94**: 1803-1806 (2002)	(95)
Korabiowska M, 2001	61	106	42	Rb	*Pathobiology* **69**: 274-280 (2001)	(96)
Moretti S, 2001	-	55	-	Ki-67	*J Am Acad Dermatol* **44**: 188-192 (2001)	(97)
Ostmeier H, 2001	-	688	-	Ki-67, MCAM, MHC Class II, CD68, Muc54, transferring receptor	*Br J Dermatol* **145**: 203-209 (2001)	(98)
Ricaniadis N, 2001	-	40	-	c-myc, HSP70, MHC Class II	*Eur J Surg Oncol* **27**: 88-93 (2001)	(99)
Korabiowska M, 2000b	-	106	-	MLH1, MSH2, PMS1, PMS2	*Anticancer Res* **20**: 4499-4505 (2000)	(100)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Retrospective/prospective cohort studies reporting incomplete immunohistochemistry methods (n=27), cont'd						
Sauroja I, 2000	-	59	-	Ki-67, HDM2, p21/WAF1, p27/KIP1, p53, Rb	*Genes Chromosomes Cancer* **28**: 404-414 (2000)	(101)
van Duinen SG, 1988	-	-	48	MHC Class I, MHC Class II	*Cancer Res* **48**: 1019-1025 (1988)	(102)
Excluded studies: Case-control study design (n=16)						
Fearfield LA, 2007	-	43	17	Fas ligand, Fas, p16/INK4A	*Br J Dermatol* **156**: 440-447 (2007)	(103)
Bauer R, 2006	161	88	101	P-cadherin	*J Clin Pathol* **59**: 699-705 (2006)	(104)
Demirkesen C, 2006	-	50	-	FGF-2, VEGF	*Pathology* **38**: 132-137 (2006)	(105)
Fecker LF, 2006	-	60	12	Bak, bax, bcl-2, bok, mcl-1, HDM2, p21/WAF1, p53, Rb, TRAIL-R1, TRAIL-R2	*J Invest Dermatol* **126**: 1366-1371 (2006)	(106)
Ivan D, 2006	-	-	26	abl-related gene, c-abl, c-Kit, PDGFRα, PDGFRβ	*J Cutan Pathol* **33**: 280-285 (2006)	(107)
Kashani-Sabet M, 2004	-	48	-	NF-κB	*J Clin Oncol* **22**: 617-623 (2004)	(108)
Sarris M, 2004	-	55	24	nm23	*Melanoma Res* **14**: 23-27 (2004)	(109)
Massi D, 1999	-	36	-	Osteonectin	*Hum Pathol* **30**: 339-344 (1999)	(110)
Otto FJ, 1999	-	182	-	Cathepsin B, cathepsin D, MMP-2	*Oncology* **56**: 208-214 (1999)	(111)
Hernberg M, 1999	-	36	-	Bcl-2, Ki-67, HDM2, p53	*Melanoma Res* **8**: 283-291 (1998)	(112)
Sparrow LE, 1998a	25	69	23	Ki-67	*Am J Dermatopathol* **20**: 12-16 (1998)	(113)
Holmes SC, 1996	-	22	-	nm23	*J Cutan Pathol* **23**: 344-349 (1996)	(114)
Hieken TJ, 1995	-	76	-	Integrin β1	*Surgery* **118**: 669-673 (1995)	(115)
Reddy VB, 1995	-	14	-	Ki-67, p53, PCNA	*J Cutan Pathol* **22**: 248-251 (1995)	(116)
Sparrow LE, 1995a	-	40	-	p53	*Melanoma Res* **5**: 387-392 (1995)	(117)
Kernohan NM, 1987	-	27	-	S100B	*Histopathology* **11**: 1285-1293 (1987)	(118)
Excluded studies: Cross-sectional study design (n=284)						
Karbowniczek M, 2008	67	40	67	mTOR	*J Invest Dermatol* **128**: 980-987 (2008) (epub Oct. 2007)	(119)
Batinac T, 2007	25	45	-	Bcl-2, Ki-67, p53, telomerase	*Coll Antropol* **31 Suppl 1**: 17-22 (2007)	(120)
Bertucci F, 2007	-	54	21	Neutral endopeptidase	*Anticancer Res* **27**: 3441-3449 (2007)	(121)
Chwirot BW, 2007	58	33	-	Cyclooxygenase-2	*Melanoma Res* **17**: 139-145 (2007)	(122)
Demirkan NC, 2007	28	24	-	β-catenin, cyclin D1, p16/INK4A	*Clin Exp Dermatol* **32**: 733-739 (2007)	(123)
Denicourt C, 2007	-	42	11	p27/KIP1	*Cancer Res* **67**: 9238-9243 (2007)	(124)
Denk AE, 2007	161	88	101	Maspin	*Pigment Cell Res* **20**: 112-119 (2007)	(125)
Einspahr JG, 2007	49	16	-	VEGF	*Cancer* **110**: 2519-2527 (2007)	(126)
Ferrari D, 2007	-	30	-	nm23	*J Cutan Pathol* **34**: 705-712 (2007)	(127)
Giehl KA, 2007	44	50	-	c-Kit, FGFR1, FGF-2, steel ligand	*J Cutan Pathol* **34**: 7-14 (2007)	(128)
Gilaberte Y, 2007	86	38	6	Galanin, α-MSH	*Actas Dermosifiliogr* **98**: 24-34 (2007)	(129)
Klein WM, 2007	71	71	84	ALCAM/CD166, nestin, CD133	*Mod Pathol* **20**: 102-107 (2007)	(130)
Lebe B, 2007	63	17	-	Cyclin D1, Ki-67	*Appl Immunohistochem Mol Morphol* **15**: 160-164 (2007)	(131)
Leotlela PD, 2007	30	28	158	Claudin-1	*Oncogene* **26**: 3846-3856 (2007)	(132)
McHugh JB, 2007	37	19	19	EZH2	*J Cutan Pathol* **34**: 597-600 (2007)	(133)
Neto DS, 2007	19	111	29	Integrin αv, integrin β3	*J Cutan Pathol* **34**: 851-856 (2007)	(134)
Pecina-Slaus N, 2007	-	70	-	β-catenin, E-cadherin	*J Cutan Pathol* **34**: 239-246 (2007)	(135)
Pisacane AM, 2007	10	45	15	CD31, CD34	*Cell Oncol* **29**: 59-66 (2007)	(136)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Cross-sectional study design (n=284), cont'd						
Polak ME, 2007	-	15	41	TGFβ-R, TGFβ2	*Br J Cancer* **96**: 1879-1887 (2007)	(137)
Pritchard-Jones RO, 2007	-	16	-	VEGF, VEGF-xxxb isoforms	*Br J Cancer* **97**: 223-230 (2007)	(138)
Puri N, 2007	20	16	24	c-Met	*Clin Cancer Res* **13**: 2246-2253 (2007)	(139)
Rakosy Z, 2007	-	9	-	EGFR	*Int J Cancer* **121**: 1729-1737 (2007)	(140)
Rothhammer T, 2007	161	88	101	BMP-7	*Cancer Biomark* **3**: 111-117 (2007)	(141)
Sanki A, 2007	19	39	34	p16/INK4A, p27/KIP1	*Pathology* **39**: 551-557 (2007)	(142)
Seidl H, 2007	5	12	34	CCR9, CCXR1, CXCR6	*Hum Pathol* **38**: 768-780 (2007)	(143)
Singh RS, 2007	35	23	31	PTEN, PI3K p110 subunit, PI3K p85 subunit	*J Cutan Pathol* **34**: 220-225 (2007)	(144)
Thies A, 2007	12	67	75	CEACAM-1, L1-CAM	*Cancer Lett* **248**: 68-80 (2007)	(145)
Weishaupt C, 2007	-	-	65	E-selectin, ICAM-1, P-selectin	*Clin Cancer Res* **13**: 2549-2556 (2007)	(146)
Wilsher M, 2007	42	91	20	WT-1	*Histopathology* **51**: 605-610 (2007)	(147)
Zygouris P, 2007	-	25	-	Bcl-2, caspase-3, caspase-8, telomerase	*J BUON* **12**: 513-519 (2007)	(148)
Arndt S, 2006	2	2	3	TANGO	*Int J Cancer* **119**: 2812-2820 (2006)	(149)
Barrow C, 2006	-	251	335	NY-ESO-1, gp100, MAGE-1, MAGE-4, MelanA, tyrosinase	*Clin Cancer Res* **12**: 764-771 (2006)	(150)
Ding Y, 2006	37	24	31	Survivin	*Cancer* **106**: 1123-1129 (2006)	(151)
Honig A, 2006	-	6	-	Tartarate-resistant acid phosphatase	*BMC Cancer* **6**: 199 (2006)	(152)
Kaariainen E, 2006	32	101	34	Fibronectin, procollagen-1, tenascin-C	*J Pathol* **210**: 181-191 (2006)	(153)
Kalogeraki A, 2006	-	-	30	c-myc, HSP-70, MHC Class II	*Anticancer Res* **26**: 3551-3554 (2006)	(154)
Kuphal S, 2006a	5	5	5	Human lethal giant larvae	*Oncogene* **25**: 103-110 (2006)	(155)
Kuphal S, 2006b	-	3	3	Dickkopf-3	*Oncogene* **25**: 5027-5036 (2006)	(156)
Kuzbicki L, 2006a	27	42	15	Lysosome-associated membrane protein-1	*Melanoma Res* **16**: 235-243 (2006)	(157)
Kuzbicki L, 2006b	17	36	11	Cyclooxygenase-2	*Melanoma Res* **16**: 29-36 (2006)	(158)
Kuzbicki L, 2006c	17	41	18	Cdk-2	*Melanoma Res* **16**: 435-444 (2006)	(159)
Massi D, 2006	10	15	5	Delta-like protein-1, jagged-1, jagged-2, notch-1, notch-2	*Mod Pathol* **19**: 246-254 (2006)	(160)
Miracco C, 2006	60	54	12	Macrophage migration inhibitory factor	*Int J Oncol* **28**: 345-352 (2006)	(161)
Mirmohammadsadegh A, 2006	-	4	19	STAT-5	*J Invest Dermatol* **126**: 2272-2280 (2006)	(162)
Niedojadlo K, 2006	75	53	24	APAF-1	*Pigment Cell Res* **19**: 43-50 (2006)	(163)
Packer L, 2006	29	67	19	Osteopontin, PTEN	*Carcinogenesis* **27**: 1778-1786 (2006)	(164)
Prieto VG, 2006	35	23	31	Galectin-3	*Clin Cancer Res* **12**: 6709-6715 (2006)	(165)
Scala S, 2006	-	-	63	CXCR4	*Clin Cancer Res* **12**: 2427-2433 (2006)	(166)
Schmidt AN, 2006	49	39	6	Estrogen receptor-α, estrogen receptor-β	*Exp Dermatol* **15**: 971-980 (2006)	(167)
Shannan B, 2006	30	18	25	Clusterin	*Anticancer Res* **26**: 2707-2716 (2006)	(168)
Simonetti O, 2006	19	40	-	CCL27, CCR10	*Eur J Cancer* **42**: 1181-1187 (2006)	(169)
Topczewska JM, 2006	-	5	10	Nodal	*Nat Med* **12**: 925-932 (2006)	(170)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Cross-sectional study design (n=284), cont'd						
Varney ML, 2006	-	82	16	CXCR1, CXCR2	*Am J Clin Pathol* **125**: 209-216 (2006)	(171)
Vereecken P, 2006	13	76	10	Maspin	*J Int Med Res* **34**: 52-57 (2006)	(172)
Winnepenninckx V, 2006	14	54	11	Securin	*Mod Pathol* **19**: 1170-1180 (2006)	(173)
Xi Y, 2006	-	18	23	IGFBP-3	*Mol Cancer Ther* **5**: 3078-3084 (2006)	(174)
Zhang H, 2006	-	7	7	Bcl-2, bcl-xL	*Int J Oncol* **28**: 661-666 (2006)	(175)
Zubieta MR, 2006	-	8	25	Galectin-1, galectin-3	*Am J Pathol* **168**: 1666-1675 (2006)	(176)
Al-Batran SE, 2005	-	-	125	NY-ESO-1, gp100, MelanA, MHC Class I, MHC Class II, tyrosinase	*Cancer Res* **65**: 3937-3941 (2005)	(177)
Baldi A, 2005	-	61	11	Ferritin light chain	*Clin Cancer Res* **11**: 3175-3183 (2005)	(178)
Brychtova S, 2005	53	74	-	Nestin	*Cesk Patol* **41**: 143-145 (2005)	(179)
Busam KJ, 2005	32	31	38	PNL2	*Am J Surg Pathol* **29**: 400-406 (2005)	(180)
Cohn ML, 2005	40	25	31	Claudin-1	*J Cutan Pathol* **32**: 533-536 (2005)	(181)
Ehrmann J, 2005	16	9	-	Nestin	*J Clin Pathol* **58**: 222-223 (2005)	(182)
Fiuraskova M, 2005	53	78	-	FGF-2, PDGF	*Anticancer Res* **25**: 4299-4303 (2005)	(183)
Hess AR, 2005	-	14	-	Focal adhesion kinase	*Cancer Res* **65**: 9851-9860 (2005)	(184)
Kuivanen T, 2005	5	63	-	MMP-13, MMP-21, MMP-26, MMP-28	*Virchows Arch* **447**: 954-960 (2005)	(185)
Kumar SM, 2005	14	9	-	Erythropoietin, erythropoietin receptor	*Am J Pathol* **166**: 823-830 (2005)	(186)
Longo-Imedio MI, 2005	7	40	-	CXCR3, CXCR4	*Int J Cancer* **117**: 861-865 (2005)	(187)
Massi D, 2005	20	40	10	Protease-activated receptor-1, protease-activated receptor-2	*Hum Pathol* **36**: 676-685 (2005)	(188)
Murry BP, 2005	-	10	35	Heparanase	*Int J Oncol* **26**: 345-352 (2005)	(189)
Pisacane AM, 2005	12	24	-	VEGF-C1, VEGF-R2/FLK	*Melanoma Res* **15**: 39-43 (2005)	(190)
Quatresooz P, 2005	48	35	-	Type IV collagen α1 chain, type IV collagen α5 chain	*Melanoma Res* **15**: 161-168 (2005)	(191)
Ramirez JA, 2005	39	58	29	Cyclin D1	*Ann Diagn Pathol* **9**: 185-188 (2005)	(192)
Redondo P, 2005	-	56	7	MMP-2, MMP-9	*Clin Exp Dermatol* **30**: 541-545 (2005)	(193)
Roesch A, 2005	52	60	60	Retinoblastoma-binding protein-2 homolog-1	*Mod Pathol* **18**: 1249-1257 (2005)	(194)
Rothhammer T, 2005	11	5	4	BMP-4, BMP-7	*Cancer Res* **65**: 448-456 (2005)	(195)
Sedghizadeh PP, 2005	8	14	-	CITED-1	*Med Sci Monit* **11**: BR189-194 (2005)	(196)
Varney ML, 2005	-	82	16	MCP-1	*Melanoma Res* **15**: 417-425 (2005)	(197)
Vereecken P, 2005	15	89	11	Galectin-3	*Arch Dermatol Res* **296**: 353-358 (2005)	(198)
Vetter CS, 2005	77	16	19	Survivin	*Arch Dermatol Res* **297**: 26-30 (2005)	(199)
Woenckhaus C, 2005	10	25	14	p27/KIP1, skp2	*Histol Histopathol* **20**: 501-508 (2005)	(200)
Zhang H, 2005	-	7	7	Survivin	*Oncol Rep* **13**: 1121-1126 (2005)	(201)
Baldi A, 2004	30	61	15	APAF-1	*Exp Dermatol* **13**: 93-97 (2004)	(202)
Becker B, 2004	9	9	14	HSP-90	*Exp Dermatol* **13**: 27-32 (2004)	(203)
Bilalovic N, 2004	-	70	28	Neutral endopeptidase	*Mod Pathol* **17**: 1251-1258 (2004)	(204)
Dissemond J, 2004	-	92	19	Calnexin, calreticulin	*Cancer Lett* **203**: 225-231 (2004)	(205)
Ellerhorst JA, 2004	60	19	-	Thyrotropin-releasing hormone	*Clin Cancer Res* **10**: 5531-5536 (2004)	(206)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Cross-sectional study design (n=284), cont'd						
Hazarika P, 2004	40	25	31	Flotillin-2	*Cancer Res* **64**: 7361-7369 (2004)	(207)
Ivan D, 2004	40	23	31	Jab1, p27/KIP1	*Mod Pathol* **17**: 811-818 (2004)	(208)
Kang SH, 2004	15	15	-	HSP-27	*J Cutan Pathol* **31**: 665-671 (2004)	(209)
Kluger HM, 2004	-	269	331	Her2/neu	*Melanoma Res* **14**: 207-210 (2004)	(210)
Krengel S, 2004	37	17	-	α-catenin, β-catenin, E-cadherin, γ-catenin, N-cadherin, P-cadherin	*J Cutan Pathol* **31**: 1-7 (2004)	(211)
Li Z, 2004	25	56	11	SOCS-1	*J Invest Dermatol* **123**: 737-745 (2004)	(212)
McNulty SE, 2004	20	-	20	c-Rel, IκB-α, IκB-β, IκB-ε, NFκB p105/p50 subunit, RelA	*Pigment Cell Res* **17**: 173-180 (2004)	(213)
Ng KC, 2004	46	87	-	XIAP-associated factor	*J Invest Dermatol* **123**: 1127-1134 (2004)	(214)
Poyraz A, 2004	-	48	-	Bax, p21/WAF1	*J Exp Clin Cancer Res* **23**: 625-631 (2004)	(215)
Schuierer MM, 2004	5	5	5	Raf-1 kinase inhibitor protein	*Cancer Res* **64**: 5186-5192 (2004)	(216)
Stefanou D, 2004	23	18	-	c-Kit, VEGF	*Int J Surg Pathol* **12**: 133-138 (2004)	(217)
Weeraratna AT, 2004	77	5	60	Calpain-3, CD74	*Oncogene* **23**: 2264-2274 (2004)	(218)
Woenckhaus C, 2004	15	38	19	p27/KIP1	*Virchows Arch* **445**: 491-497 (2004)	(219)
Banfalvi T, 2003	-	37	22	S100B	*Oncology* **64**: 374-379 (2003)	(220)
Behrmann I, 2003	9	15	14	Methyladenosine phosphorylase	*Am J Pathol* **163**: 683-690 (2003)	(221)
Bernard K, 2003	14	10	-	Hepatoma-derived growth factor	*Cancer Res* **63**: 6716-6725 (2003)	(222)
Dissemond J, 2003	-	85	19	Tapasin	*Arch Dermatol Res* **295**: 43-49 (2003)	(223)
Ekmekcioglu S, 2003	-	38	43	iNOS, IL-24	*Mol Cancer Ther* **2**: 9-17 (2003)	(224)
Fogel M, 2003	26	24	24	L1-CAM	*Cancer Lett* **189**: 237-247 (2003)	(225)
Goulet AC, 2003	10	23	16	Cyclooxygenase-2	*Cancer Biol Ther* **2**: 713-718 (2003)	(226)
Hafnet C, 2003	8	7	9	EphB6	*Int J Oncol* **23**: 1553-1559 (2003)	(227)
Haritopoulos KN, 2003	-	57	9	Integrin β3, ICAM-1	*APMIS* **111**: 421-429 (2003)	(228)
Keehn CA, 2003	21	8	2	Ets-1	*Mod Pathol* **16**: 772-777 (2003)	(229)
Miranda E, 2003	10	32	-	Apolipoprotein D	*J Surg Oncol* **83**: 99-105 (2003)	(230)
Potti A, 2003a	-	202	-	Her2/neu	*Anticancer Res* **23**: 4067-4069 (2003)	(231)
Redondo P, 2003	-	42	9	FGF-2, VEGF	*J Am Acad Dermatol* **49**: 255-263 (2003)	(232)
Ribatti D, 2003	25	46	21	FGF-2	*Eur J Cancer* **39**: 666-674 (2003)	(233)
Rosenwald IB, 2003	6	9	-	Cyclin D1, eIF-2α, eIF-4E	*Cancer* **98**: 1080-1088 (2003)	(234)
Sander CS, 2003	18	18	-	Catalase, SOD-cu/zn, SOD-mn	*Br J Dermatol* **148**: 913-922 (2003)	(235)
Shen SS, 2003	35	23	31	abl-related gene, c-abl, c-Kit, PDGFR-α, PDGFR-β	*J Cutan Pathol* **30**: 539-547 (2003)	(236)
Slater M, 2003	-	80	-	Calcium channel receptors P2X-1, P2X-2, P2X-3, P2X-4, P2X-5, P2X-6, P2X-7, P2Y-2, Caspase-3, E-cadherin, telomerase	*Melanoma Res* **13**: 137-145 (2003)	(237)
Sundram U, 2003	15	30	14	IRF4, S100B, gp100, MelanA	*Mod Pathol* **16**: 802-810 (2003)	(238)
Wang H, 2003	40	23	31	IGFBP-2	*J Cutan Pathol* **30**: 599-605 (2003)	(239)
Xu X, 2003	10	47	16	Trk-C	*J Cutan Pathol* **30**: 318-322 (2003)	(240)
Baldi A, 2002	-	total n=50		HtrA1	*Oncogene* **21**: 6684-6688 (2002)	(241)
Demunter A, 2002	0	48	32	β-catenin	*Mod Pathol* **15**: 454-461 (2002)	(242)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Cross-sectional study design (n=284), cont'd						
Dhawan P, 2002	17	-	12	Akt, NF-κB	*Cancer Res* **62**: 7335-7342 (2002)	(243)
Dobrowolski R, 2002	14	12	6	p14/ARF	*Arch Dermatol Res* **293**: 545-551 (2002)	(244)
Ellerhorst JA, 2002	-	41	41	IL-24	*J Clin Oncol* **20**: 1069-1074 (2002)	(245)
Goncharuk VN, 2002	19	16	-	Fascin	*J Cutan Pathol* **29**: 430-438 (2002)	(246)
Kanitakis J, 2002	-	28	44	Neutral endopeptidase	*Melanoma Res* **12**: 241-244 (2002)	(247)
Kim SH, 2002	-	6	3	Interferon-inducible protein kinase	*Oncogene* **21**: 8741-8748 (2002)	(248)
Kneisel L, 2002	-	36	-	Polo-like kinase	*J Cutan Pathol* **29**: 354-358 (2002)	(249)
Kurschat P, 2002	-	41	6	MT1-MMP, MMP-2, TIMP-2	*J Pathol* **197**: 179-187 (2002)	(250)
Nouman GS, 2002	27	50	-	ING1b/p33	*Histopathology* **40**: 360-366 (2002)	(251)
Pavey SJ, 2002	-	108	-	p16/INK4A	*Melanoma Res* **12**: 539-547 (2002)	(252)
Redondo P, 2002	-	42	9	Fas ligand, Fas/CD95	*Br J Dermatol* **147**: 80-86 (2002)	(253)
Simonetti O, 2002	25	28	-	MMP-2, MMP-9, VEGF	*Cancer* **95**: 1963-1970 (2002)	(254)
Timar J, 2002	-	54	-	Autocrine motility factor receptor	*Clin Exp Metastasis* **19**: 225-232 (2002)	(255)
Touab M, 2002	20	11	8	Versican	*Am J Pathol* **160**: 549-557 (2002)	(256)
Winer I, 2002	12	12	-	12-lipoxygenase	*Melanoma Res* **12**: 429-434 (2002)	(257)
Ahrens T, 2001	7	6	5	CD44, hyaluronan-mediated motility receptor, ICAM-1	*J Invest Dermatol* **116**: 93-101 (2001)	(258)
Baldi A, 2001	36	53	10	AP-2, c-Kit, E-cadherin, p21/WAF1	*J Cell Biochem* **83**: 364-372 (2001)	(259)
Bodey B, 2001	-	17	-	MMP-2, MMP-3, MMP-9, MMP-10, MMP-13	*In Vivo* **15**: 57-64 (2001)	(260)
de Vries TJ, 2001	-	44	86	gp100, MelanA, S100B, tyrosinase	*J Pathol* **193**: 13-20 (2001)	(261)
Demunter A, 2001	76	66	17	Endothelin-B receptor	*Virchows Arch* **438**: 485-491 (2001)	(262)
Denkert C, 2001	4	28	-	Cyclooxygenase-2	*Cancer Res* **61**: 303-308 (2001)	(263)
Fang D, 2001	10	9	42	Microtubule-associated protein-2	*Am J Pathol* **158**: 2107-2115 (2001)	(264)
Fink-Puches R, 2001	-	20	10	Her2/neu	*Anticancer Res* **21**: 2793-2795 (2001)	(265)
Frahm SO, 2001	-	167	-	Ki-67	*Hum Pathol* **32**: 1376-1381 (2001)	(266)
Georgieva J, 2001	12	49	18	Cyclin A, cyclin B1, cyclin D1, cyclin D2, cyclin D3, cyclin E, cdk-1, cdk-2, cdk-4	*J Clin Pathol* **54**: 229-235 (2001)	(267)
Gilhooly EM, 2001	5	-	10	Protein kinase C-β	*Melanoma Res* **11**: 355-369 (2001)	(268)
Hussein MR, 2001	41	9	-	MLH1, MSH2, MSH6	*Am J Dermatopathol* **23**: 308-314 (2001)	(269)
Innominato PF, 2001	16	15	12	BDNF, NGF, NT-3, NT-4/5, $p75^{NTR}$, Trk-A, Trk-B, Trk-C	*J Pathol* **194**: 95-100 (2001)	(270)
King R, 2001	62	58	-	MITF	*Am J Surg Pathol* **25**: 51-57 (2001)	(271)
Loggini B, 2001	-	49	-	Bcl-2, p-glycoprotein, p53, PCNA	*Tumori* **87**: 179-186 (2001)	(272)
Massi D, 2001	34	50	8	iNOS	*J Pathol* **194**: 194-200 (2001)	(273)
Polsky D, 2001a	10	6	5	p16/INK4A	*Cancer Res* **61**: 6008-6011 (2001)	(274)
Polsky D, 2001b	16	118	38	HDM2	*Cancer Res* **61**: 7642-7646 (2001)	(275)
Quintela I, 2001	10	35	-	Pepsinogen C	*Int Jbiol Markers* **16**: 240-244 (2001)	(276)
Ahmed B, 2000	41	52	13	iNOS	*Br J Dermatol* **142**: 432-440 (2000)	(277)
Aroni K, 2000	-	57	9	Vasopressin	*Melanoma Res* **10**: 535 (2000)	(278)
Bergman R, 2000	10	9	29	MelanA	*J Am Acad Dermatol* **42**: 496-500 (2000)	(279)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Cross-sectional study design (n=284), cont'd						
Busam KJ, 2000	132	85	120	MAGE-3	*Mod Pathol* **13**: 459-465 (2000)	(280)
Hofman UB, 2000a	-	26	20	MMP-2	*J Invest Dermatol* **115**: 625-632 (2000)	(281)
Hofman UB, 2000b	15	25	20	MT1-MMP, MMP-2, TIMP-2	*J Pathol* **191**: 245-256 (2000)	(282)
Kanter-Lewensohn L, 2000	62	73	29	IGFR-1, p27/KIP1	*Growth Factors* **17**: 193-202 (2000)	(283)
Leiter U, 2000	10	9	29	Bax, bcl-2, bcl-xL/xS	*Arch Dermatol Res* **292**: 225-232 (2000)	(284)
Persons DL, 2000	-	40	-	Her2/neu	*Anticancer Res* **20**: 1965-1968 (2000)	(285)
van Klempen LC, 2000	38	55	28	ALCAM/CD166	*Am J Pathol* **156**: 769-774 (2000)	(286)
Ahmed B, 1999	100	59	18	nNOS, protein inhibitor of NOS	*Br J Dermatol* **141**: 12-19 (1999)	(287)
Bayer-Garner IB, 1999	34	50	8	VEGF	*Mod Pathol* **12**: 770-774 (1999)	(288)
Birck A, 1999	10	19	20	FGF-2, VEGF	*Melanoma Res* **9**: 375-381 (1999)	(289)
Boni R, 1999	27	32	23	Cellular apoptosis susceptibility gene	*Am J Dermatopathol* **21**: 125-128 (1999)	(290)
Chiodino C, 1999	8	11	2	GM-CSF	*J Invest Dermatol* **113**: 415-418 (1999)	(291)
Easty DJ, 1999	13	22	6	EphA2, Ephrin-A1	*Int J Cancer* **84**: 494-501 (1999)	(292)
Goldmann T, 1999	-	147	-	Cathepsin B, cathepsin D, MMP-2	*Pathol Res Pract* **195**: 171-175 (1999)	(293)
Grossman D, 1999	-	15	15	Survivin	*J Invest Dermatol* **113**: 1076-1081 (1999)	(294)
Hartmann A, 1999	8	10	15	Angiogenin	*Cancer Res* **59**: 1578-1583 (1999)	(295)
Korabiowska M, 1999	25	53	36	Bax, bcl-2	*Pol J Pathol* **50**: 17-21 (1999)	(296)
Lowney JK, 1999	-	30	10	IRF-1, IRF-2	*Ann Surg Oncol* **6**: 604-608 (1999)	(297)
Moretti S, 1999	10	20	10	c-Kit, GM-CSF, GM-CSFR, IL-1α, IL-1β, IL-1R, IL-2, IL-2R, IL-6, IL-6R, IL-8, IL-8R, steel ligand, TGF-β, type III TGF-βR, TNF-α, TNF-β, p55 TNFR, p75 TNFR	*Int J Cancer* **84**: 160-168 (1999)	(298)
Ozer E, 1999	24	28	8	Ki-67	*Anal Quant Cytol Histol* **21**: 42-46 (1999)	(299)
Reed JA, 1999	25	40	10	GAP-43, NCAM, $p75^{NTR}$	*Am J Pathol* **155**: 549-555 (1999)	(300)
Sanders DS, 1999	30	30	10	β-catenin, desmoglein, E-cadherin, γ-catenin, N-cadherin, P-cadherin	*Mol Pathol* **52**: 151-157 (1999)	(301)
Singh RK, 1999	-	36	10	IL-8	*Melanoma Res* **9**: 383-387 (1999)	(302)
Sparrow LE, 1999	33	47	30	EGFR	*Australas J Dermatol* **40**: 19-24 (1999)	(303)
Tschugguel W, 1999	-	-	25	iNOS	*Br J Cancer* **79**: 1609-1612 (1999)	(304)
Van Belle PA, 1999	41	56	26	Integrin β3	*Hum Pathol* **30**: 562-567 (1999)	(305)
Vlaykova T, 1999a	-	-	70	VEGF	*Melanoma Res* **9**: 59-68 (1999)	(306)
Zhang XD, 1999	13	34	20	α-catenin, β-catenin, γ-catenin, p120-catenin	*Pathology* **31**: 239-246 (1999)	(307)
Bergman R, 1998	27	17	-	c-fos	*Am J Dermatopathol* **20**: 262-265 (1998)	(308)
Betke H, 1998	29	59	32	nm23	*Pol J Pathol* **49**: 93-96 (1998)	(309)
Busam KJ, 1998	50	40	-	MelanA	*Am J Surg Pathol* **22**: 976-982 (1998)	(310)
Cormier JN, 1998	-	78	139	gp100, melanA, MHC Class I	*Int J Cancer* **75**: 517-524 (1998)	(311)
Goldmann T, 1998	-	147	-	Cathepsin B, cathepsin D, MMP-2, metallothionein, PCNA	*J Exp Clin Cancer Res* **17**: 483-489 (1998)	(312)
Grant SW, 1998	-	41	58	Thrombospondin-1	*Cancer Detect Prev* **22**: 185-194 (1998)	(313)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Cross-sectional study design (n=284), cont'd						
Hensley C, 1998	9	27	9	GM-CSF, IL-8	*Exp Dermatol* **7**: 335-341 (1998)	(314)
Hofbauer GF, 1998a	41	31	19	Tyrosinase	*J Cutan Pathol* **25**: 204-209 (1998)	(315)
Hofbauer GF, 1998b	39	34	23	MelanA	*Melanoma Res* **8**: 337-343 (1998)	(316)
Keller-Melchior R, 1998	51	24	33	p16/INK4A, Rb	*J Invest Dermatol* **110**: 932-938 (1998)	(317)
Khare VK, 1998	33	35	5	Substance P	*J Cutan Pathol* **25**: 2-10 (1998)	(318)
Silye R, 1998	20	59	11	α-catenin, β-catenin, E-cadherin, γ-catenin	*J Pathol* **186**: 350-355 (1998)	(319)
Sparrow LE, 1998b	36	50	25	p16/INK4A, p21/WAF1	*Am J Dermatopathol* **20**: 255-261 (1998)	(320)
Tang L, 1998	5	10	5	Bax, bcl-2, bcl-xL, bcl-xS, mcl-1	*Clin Cancer Res* **4**: 1865-1871 (1998)	(321)
van den Oord JJ, 1998	44	60	6	Dipeptidyl peptidase IV/CD26	*Br J Dermatol* **138**: 615-621 (1998)	(322)
Boni R, 1997	-	39	-	S100A1, S100A2, S100A4, S100A6, S100B	*J Cutan Pathol* **24**: 76-80 (1997)	(323)
de Vries TJ, 1997	26	38	41	gp100, MelanA, tyrosinase	*Cancer Res* **57**: 3223-3229 (1997)	(324)
Erhard H, 1997	-	24	-	VEGF	*Melanoma Res* **7 Suppl 2**: S19-S26 (1997)	(325)
Jager E, 1997	-	-	20	MelanA, MHC Class I, tyrosinase	*Int J Cancer* **71**: 142-147 (1997)	(326)
Korabiowska M, 1997	29	59	-	GADD34, GADD45, GADD153, p53	*Anticancer Res* **17**: 3697-3700 (1997)	(327)
Ledda F, 1997	25	7	29	Osteonectin	*J Invest Dermatol* **108**: 210-214 (1997)	(328)
Marcoval J, 1997	-	46	-	VEGF	*J Cutan Pathol* **24**: 212-218 (1997)	(329)
Montone KT, 1997	34	31	20	c-Kit	*Mod Pathol* **10**: 939-944 (1997)	(330)
Moretti S, 1997	12	30	11	TGF-β, TGF-β3	*Melanoma Res* **7**: 313-321 (1997)	(331)
Nicotra MR, 1997	30	46	32	MelanA	*J Immunother* **20**: 466-469 (1997)	(332)
Reichrath J, 1997	38	22	47	nm23	*Dermatology* **194**: 136-139 (1997)	(333)
Rudolph P, 1997	292	92	-	Ki-67	*J Am Acad Dermatol* **37**: 169-178 (1997)	(334)
Salven P, 1997	6	22	33	VEGF	*Br J Cancer* **76**: 930-934 (1997)	(335)
Seelentag WK, 1997	-	28	9	CD44, CD44v3, CD44v4, CD44v5, CD44v6, CD44v9	*J Cutan Pathol* **24**: 206-211 (1997)	(336)
Trotter MJ, 1997	25	23	12	p21/WAF1	*J Cutan Pathol* **24**: 265-271 (1997)	(337)
van den Oord JJ, 1997a	33	41	-	EMMPRIN, MMP-9	*Am J Pathol* **151**: 665-670 (1997)	(338)
Weiss J, 1997	60	86	17	Rap1-GAP	*Arch Dermatol Res* **289**: 573-577 (1997)	(339)
Brasoveanu LI, 1996	6	12	20	Protectin/CD59	*Lab Invest* **74**: 33-42 (1996)	(340)
Danen EH, 1996	36	27	35	E-cadherin	*Melanoma Res* **6**: 127-131 (1996)	(341)
de Vries TJ, 1996a	38	32	35	Plasminogen, tetranectin	*J Pathol* **179**: 260-265 (1996)	(342)
de Vries TJ, 1996	34	36	37	Lipoprotein receptor-related protein receptor-associated protein, α2-macroglobulin receptor	*Cancer Res* **56**: 1432-1439 (1996)	(343)
Easty DJ, 1996	10	16	5	nm23	*Br J Cancer* **74**: 109-114 (1996)	(344)
Francia G, 1996	11	8	1	Annexin VI	*Cancer Res* **56**: 3855-3858 (1996)	(345)
Harwood CA, 1996	19	81	6	CD44, CD44v3, CD44v4/5, CD44v6, CD44v8/9	*Br J Dermatol* **135**: 876-882 (1996)	(346)
Lee CS, 1996	9	40	2	nm23	*Pathology* **28**: 220-224 (1996)	(347)
Marincola FM, 1996	-	-	14	gp100, MelanA	*J Immunother Emphasis Tumor Immunol* **19**: 192-205 (1996)	(348)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Cross-sectional study design (n=284), cont'd						
Reed JA, 1996	27	58	-	IL-3	*J Cutan Pathol* **23**: 495-505 (1996)	(349)
Simon JC, 1996	13	16	18	CD44	*Eur J Cancer* **32A**: 1394-1400 (1996)	(350)
Van Belle P, 1996	8	26	17	TGF-β1, TGF-β2, TGF-β3	*Am J Pathol* **148**: 1887-1894 (1996)	(351)
Xerri L, 1996	-	10	-	FGFR1	*Melanoma Res* **6**: 223-230 (1996)	(352)
Brasoveanu LI, 1995	-	-	54	Protectin/CD59	*Int J Cancer* **61**: 548-556 (1995)	(353)
Cerroni L, 1995	35	29	-	Bcl-2	*Am J Dermatopathol* **17**: 7-11 (1995)	(354)
Chetty R, 1995	-	32	-	T-cell acute leukemia gene (TAL1)	*Melanoma Res* **5**: 251-254 (1995)	(355)
Danen EH, 1995	28	29	24	Integrin αv, integrin β3, integrin β5	*Int J Cancer* **61**: 491-496 (1995)	(356)
Gelsleichter L, 1995	22	38	42	HDM2, p53	*Mod Pathol* **8**: 530-535 (1995)	(357)
Korabiowska M, 1995	62	121	82	c-myc, Ki-67	*In Vivo* **9**: 433-438 (1995)	(358)
Lee CS, 1995	7	27	-	p53	*Australas J Dermatol* **36**: 192-195 (1995)	(359)
Mirecka J, 1995	63	97	-	gp100, S100B	*Pol J Pathol* **46**: 167-172 (1995)	(360)
Natali PG, 1995	9	15	26	Fibronectin, integrin α3, integrin α4, integrin α5, integrin αv, integrin β1, integrin β3	*Br J Cancer* **71**: 1243-1247 (1995)	(361)
Platz A, 1995	20	33	52	p53, N-ras	*Melanoma Res* **5**: 101-106 (1995)	(362)
Podhajcer OL, 1995	37	11	10	Cathepsin D	*J Invest Dermatol* **104**: 340-344 (1995)	(363)
Poremba C, 1995	-	58	5	HDM2, p53	*Oncol Res* **7**: 331-339 (1995)	(364)
Ramsay JA, 1995b	39	39	21	Bcl-2	*Mod Pathol* **8**: 150-154 (1995)	(365)
Reed JA, 1995	38	51	14	p16/INK4A	*Cancer Res* **55**: 2713-2718 (1995)	(366)
Rudolph P, 1995	211	85	18	gp100, Ki-67, topoisomerase-IIα	*Am J Pathol* **147**: 1615-1625 (1995)	(367)
Schadendorf D, 1995b	10	29	39	Gamma glutamyl transferase, glutathione-S-reductase, glutathione-S-transferase	*J Invest Dermatol* **105**: 109-112 (1995)	(368)
Sparrow LE, 1995b	61	58	21	p53	*Melanoma Res* **5**: 93-100 (1995)	(369)
Weiss J, 1995	-	113	43	p53	*Br J Dermatol* **133**: 23-31 (1995)	(370)
Danen EH, 1994	38	52	25	Integrin α1, integrin α2, integrin α3, integrin α4, integrin α5, integrin α6, integrin α-IIb, integrin αv, integrin β1, integrin β3, integrin β4	*Histopathology* **24**: 249-256 (1994)	(371)
de Vries TJ, 1994	31	19	17	PAI-1, PAI-2, tPA, uPA, uPAR	*Am J Pathol* **144**: 70-81 (1994)	(372)
Saenz-Santamaria MC, 1994	10	10	4	Bcl-2, Ki-67	*J Cutan Pathol* **21**: 393-397 (1994)	(373)
Si Z, 1994	-	34	21	CD44. cutaneous lymphocyte-associated antigen, integrin αv, integrin β2, integrin β3, ICAM-1, LeCAM-1, thrombospondin receptor, thrombospondin-1, vitronectin	*Pathology* **26**: 6-15 (1994)	(374)
van den Oord JJ, 1994	15	13	11	Bcl-2	*Am J Pathol* **145**: 294-300 (1994)	(375)
von Schoultz E, 1994	-	11	12	Estramustine binding protein	*Melanoma Res* **4**: 401-405 (1994)	(376)
Bishop PW, 1993	-	55	35	α-smooth muscle actin, CAM 5.2, gp100, granulophysin/CD63, S100B	*Histopathology* **23**: 159-166 (1993)	(377)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Cross-sectional study design (n=284), cont'd						
Carrel S, 1993	-	61	96	Neutral endopeptidase	*Melanoma Res* **3**: 319-323 (1993)	(378)
Lassam NJ, 1993	82	61	10	p53	*Cancer Res* **53**: 2235-2238 (1993)	(379)
McGregor JM, 1993	46	24	12	p53	*Br J Dermatol* **128**: 606-611 (1993)	(380)
Natali PG, 1993	20	23	44	c-Met	*Br J Cancer* **68**: 746-750 (1993)	(381)
Rieger E, 1993	16	43	18	Ki-67, PCNA	*J Cutan Pathol* **20**: 229-236 (1993)	(382)
Schadendorf D, 1993	10	40	11	Integrin α1, integrin α2, integrin α3, integrin α4, integrin α5, integrin α6, integrin αv, integrin β2, integrin β3	*J Pathol* **170**: 429-434 (1993)	(383)
Vacca A, 1993	29	52	16	67 kDa laminin receptor	*Cancer* **72**: 455-461 (1993)	(384)
de Wit PE, 1992	29	48	22	EGFR	*J Invest Dermatol* **99**: 168-173 (1992)	(385)
Denton KJ, 1992	18	32	37	E-selectin, ICAM-1, MCAM, NCAM, VCAM-1	*J Pathol* **167**: 187-191 (1992)	(386)
Jonjic N, 1992	26	26	31	VCAM-1	*Am J Pathol* **141**: 1323-1330 (1992)	(387)
Natali PG, 1991	16	32	29	Integrin α6, integrin β1	*Int J Cancer* **49**: 168-172 (1991)	(388)
Stretch JR, 1991	3	20	33	p53	*Cancer Res* **51**: 5976-5979 (1991)	(389)
Takahashi H, 1991	63	46	30	PCNA	*Histopathology* **18**: 221-227 (1991)	(390)
Wollina U, 1991	98	28	7	Calmodulin, fibronectin, gp100, ICAM-1, Ki-67, MHC Class II, granulophysin, S100B	*Anticancer Res* **11**: 1405-1414 (1991)	(391)
Cho KH, 1990	60	52	9	S100	*Cancer* **66**: 765-771 (1990)	(392)
Cohen C, 1990	-	5	28	Estrogen receptor-α	*Am J Dermatopathol* **12**: 562-564 (1990)	(393)
Natali PG, 1990	51	95	98	ICAM-1	*Cancer Res* **50**: 1271-1278 (1990)	(394)
van Muijen GN, 1990	88	31	34	Transferrin receptor	*J Invest Dermatol* **95**: 65-69 (1990)	(395)
Zarbo RJ, 1990	-	64	-	Cytokeratin	*Mod Pathol* **3**: 494-501 (1990)	(396)
Johnson PJ, 1989	83	93	46	ICAM-1	*Proc Natl Acad Sci USA* **86**: 641-644 (1989)	(397)
Kaudewitz P, 1989	-	72	-	Ki-67	*Am J Pathol* **134**: 1063-1068 (1989)	(398)
Smolle J, 1989	8	10	7	Ki-67	*Am J Dermatopathol* **11**: 301-307 (1989)	(399)
Natali PG, 1987	44	39	52	Melanoma-associated antigen p97	*Cancer* **59**: 55-63 (1987)	(400)
Hagen EC, 1986	-	39	21	Granulophysin, S100B	*Histopathology* **11**: 689-700 (1986)	(401)
Ruiter DJ, 1984	25	14	24	MHC Class I, MHC Class II, β2-microglobulin	*Cancer Res* **44**: 3930-3935 (1984)	(402)
Excluded studies: Case series study design (n=53)						
Chakravarti N, 2007	49	130	47	RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ	*Clin Cancer Res* **13**: 4817-4824 (2007)	(403)
Mihic-Probst D, 2007	20	64	165	Bmi-1	*Int J Cancer* **121**: 1764-1770 (2007)	(404)
Mnich CD, 2007	-	60	-	SMAD-2	*Melanoma Res* **17**: 131-136 (2007)	(405)
Tchernev G, 2007	-	31	1	Bak, bax, bcl-2, cyclin E, Ki-67, HDM2, p16/INK4A, p21/WAF1, p27/KIP1, p53, Rb	*J Cutan Pathol* **34**: 247-256 (2007)	(406)
Velazquez EF, 2007a	-	61	41	NY-ESO-1	*Cancer Immun* **7**: 11 (2007)	(407)
Velazquez EF, 2007b	-	33	60	Neutral endopeptidase	*J Transl Med* **5**: 2 (2007)	(408)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Case series study design (n=53), cont'd						
Zhuang L, 2007	20	42	38	AP-2α, bcl-2, bcl-xL, mcl-1, MITF, STAT-3	*Mod Pathol* **20**: 416-426 (2007)	(409)
Monteagudo C, 2006	-	82	-	CXCR3	*J Clin Pathol* **epub** (2006)	(410)
Tang L, 2006	10	154	54	Collagen-triple-helix-repeat-containing 1	*Clin Cancer Res* **12**: 3716-3722 (2006)	(411)
Wild PJ, 2006	161	88	101	Methyladenosine phosphorylase	*Arch Dermatol* **142**: 471-476 (2006)	(412)
Zhuang L, 2006	20	42	38	TRAIL-R1, TRAIL-R2, TRAIL-R3/4	*Hum Pathol* **37**: 1286-1294 (2006)	(413)
Corte MD, 2005	8	51	-	MMP-13	*Int J Biol Markers* **20**: 242-248 (2005)	(414)
Roesch A, 2005b	60	-	60	Rb	*Mod Pathol* **18**: 565-572 (2005)	(415)
Wu H, 2005	23	34	34	Pleiotrophin	*J Cutan Pathol* **32**: 125-130 (2005)	(416)
Bron LP, 2004	-	45	-	TRAIL ligand	*Pathology* **36**: 561-565 (2004)	(417)
Forster-Horvath C, 2004	-	28	-	Vascular adhesion protein-1	*Melanoma Res* **14**: 135-140 (2004)	(418)
Innocenzi D, 2003	30	77	30	Fatty acid synthase	*J Cutan Pathol* **30**: 23-28 (2003)	(419)
Jonjic N, 2003	-	48	-	PCNA	*Clin Exp Dermatol* **28**: 310-314 (2003)	(420)
Woenckhaus C, 2003	16	20	30	AP-2α, caspase-3, caspase-6, c-Kit	*J Pathol* **201**: 278-287 (2003)	(421)
Brinck U, 2002	-	59	-	p53, p63	*Int J Mol Med* **10**: 707-711 (2002)	(422)
Dawn G, 2002	16	24	-	Endoglin/CD105	*Clin Exp Dermatol* **27**: 153-156 (2002)	(423)
Eliopoulos P, 2002	-	62	-	Her2/neu	*Melanoma Res* **12**: 139-145 (2002)	(424)
Middleman BR, 2002	54	37	-	GROα	*Mod Pathol* **15**: 532-537 (2002)	(425)
Berset M, 2001	-	73	-	MelanA	*Int J Cancer* **95**: 73-77 (2001)	(426)
Kamarashev J, 2001	-	38	-	Proteasomal subunits LMP2 & LMP7, transporter associated with antigen processing-1 & -2	*Int J Cancer* **95**: 23-28 (2001)	(427)
Nikkola J, 2001	-	-	37	MMP-1, MMP-13	*Melanoma Res* **11**: 157-166 (2001)	(428)
Korabiowska M, 2000a	61	106	42	Ki-67	*AnticancerRes* **20**: 1781-1786 (2000)	(429)
Salti GI, 2000	-	63	-	MITF	*Cancer Res* **60**: 5012-5016 (2000)	(430)
Strebhardt K, 2000	-	175	-	Polo-like kinase	*JAMA* **283**: 479-480 (2000)	(431)
Vihinen P, 2000	-	-	38	Integrin α1, integrin α2, integrin α6, integrin αv, integrin β1	*Melanoma Res* **10**: 243-251 (2000)	(432)
Ciotti P, 1999	-	16	18	GM-CSF, ICAM-1	*Melanoma Res* **9**: 253-260 (2000)	(433)
Vlaykova T, 1999b	-	-	60	Ki-67	*Oncology* **57**: 242-252 (1999)	(434)
Boni R, 1998	15	62	-	c-myc	*Dermatology* **196**: 288-291 (1998)	(435)
Essner R, 1998	-	28	35	p53	*Cancer* **82**: 309-316 (1998)	(436)
Florenes VA, 1998	4	113	45	p27/KIP1	*Am J Pathol* **153**: 305-312 (1998)	(437)
Healy E, 1998	32	39	-	Ki-67, p21/WAF1, p53	*Oncogene* **16**: 2213-2218 (1998)	(438)
Konstadoulakis MM, 1998	-	40	25	c-myc, HSP-70, MHC Class II	*Ann Surg Oncol* **5**: 253-260 (1998)	(439)
Bjornhagen V, 1997	-	23	39	PCNA	*Scand J Plast Reconstr Surg Hand Surg* **31**: 109-118 (1997)	(440)
Dietrich A, 1997	-	92	-	CD44	*Eur J Cancer* **33**: 926-930 (1997)	(441)
Natali PG, 1997	20	39	34	Integrin αv, integrin β3, ICAM-1	*Cancer Res* **57**: 1554-1560 (1997)	(442)
van den Oord JJ, 1997	41	71	-	nm23	*Melanoma Res* **7**: 121-128 (1997)	(443)
Vielkind JR, 1997	-	60	22	Xmrk-2	*J Cutan Pathol* **24**: 620-627 (1997)	(444)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Case series study design (n=53), cont'd						
Boni R, 1996	-	34	-	Ki-67	*J Am Acad Dermatol* **35**: 416-418 (1996)	(445)
Hieken TJ, 1996	-	160	-	Integrin β3	*J Surg Res* **63**: 169-173 (1996)	(446)
Maelandsmo GM, 1996	4	126	46	p21/WAF1	*Am J Pathol* **149**: 1813-1822 (1996)	(447)
van den Oord JJ, 1996	71	71	28	CD40	*Am J Pathol* **149**: 1953-1961 (1996)	(448)
Lazaris AC, 1995	-	60	-	c-myc, HSP-70, MHC Class II	*Virchows Arch* **426**: 461-467 (1995)	(449)
Schadendorf D, 1995a	-	60	-	CD44v6, E-selectin, integrin α4, integrin α6, ICAM-1, P-selectin	*J Natl Cancer Inst* **87**: 366-371 (1995)	(450)
Casazza S, 1993	-	48	10	p53	*Pathologica* **85**: 335-342 (1993)	(451)
Woosley JT, 1993	-	16	-	PCNA	*J Cutan Pathol* **20**: 498-503 (1993)	(452)
Zelger B, 1993	22	59	14	Metallothionein	*Histopathology* **23**: 257-263 (1993)	(453)
Soyer HP, 1991	38	72	35	Ki-67	*J Cutan Pathol* **18**: 264-272 (1991)	(454)
Natali PG, 1988	54	85	62	Melanoma CEA-like antigen	*Int J Biol Markers* **3**: 211-220 (1988)	(455)
Excluded studies: Tumor compartment not assayed (n=6)						
Pocza P, 2008	Evaluated expression in stromal compartments				*Int J Cancer* **122**: 1972-1980 (2008)	(456)
Brezillon S, 2007	Evaluated expression in stromal compartments				*Clin Exp Dermatol* **32**: 405-416 (2007)	(457)
Huszar M, 2006	Multi-tissue survey of L1-CAM expression				*Hum Pathol* **37**: 1000-1008 (2006)	(458)
Straume O, 2003	Evaluated expression in vascular compartment				*Angogenesis* **6**: 295-301 (2003)	(459)
Hussein MR, 2002	Data redundant with another cross-sectional study (Hussein MR, 2001)				*Mol Carcinog* **34**: 35-44 (2002)	(460)
van Duinen CM, 1994	Evaluated expression in stromal compartments				*Histopathology* **24**: 33-40 (1994)	(461)
Excluded studies: Non-Caucasian sample (n=30)						
Tao J, 2008	Study done on an Asian population from Tongji Hospital, China				*Br J Dermatol* **158**: 88-94 (2008)	(462)
Kawasaki K, 2007	Study done on an Asian population from Kanagawa, Japan				*Br J Dermatol* **156**: 613-619 (2007)	(463)
Liao Y-H, 2007	Study done on an Asian population from Taiwan, R.O.C.				*Cancer Res* **67**: 11547-11556 (2007)	(464)
Wu Y, 2007	Study done on an Asian population from Huazhong University, China				*Zhonghua Bing Li Xue Za Zhi* **36**: 466-469 (2007)	(465)
Nishimura K, 2006	Study done on an Asian population from Mie University, Japan				*Anticancer Res* **26**: 4349-4356 (2006)	(466)
Mustika R, 2005	Study done on an Asian population from Kobe University, Japan				*Pigment Cell Res* **18**: 59-62 (2005)	(467)
Nishizawa A, 2005	Study done on an Asian population from Tokyo, Japan				*Cancer* **103**: 1693-1700 (2005)	(468)
Kageshita T, 2003	Study done on an Asian population from Kumamoto University, Japan				*Br J Dermatol* **148**: 533-538 (2003)	(469)
Koganehira Y, 2003	Study done on an Asian population from Shinshu University, Japan				*Br J Dermatol* **148**: 971-980 (2003)	(470)
Sato H, 2002	Study done on an Asian population from Kobe University, Japan				*Pigment Cell Res* **15**: 98-103 (2002)	(471)
Shukuwa T, 2002	Study done on an Asian population from Nagasaki University, Japan				*Mod Pathol* **15**: 387-396 (2002)	(472)
Kageshita T, 2001a	Study done on an Asian population from Kumamoto University, Japan				*J Dermatol Sci* **25**: 36-44 (2001)	(473)
Kageshita T, 2001b	Study done on an Asian population from Kumamoto University, Japan				*Pigment Cell Res* **14**: 195-200 (2001)	(474)
Sugita K, 2001	Study done on an Asian population from Kitakyushu, Japan				*Am J Dermatopathol* **23**: 29-35 (2001)	(475)
Kageshita T, 2000	Study done on an Asian population from Kumamoto University, Japan				*Cancer Immunol Immunother* **49**: 314-318 (2000)	(476)
Torisu-Itakura H, 2000	Study done on an Asian population from Fukuoka, Japan				*Jpn J Cancer Res* **91**: 906-910 (2000)	(477)
Funasaka Y, 1999	Study done on an Asian population from Kobe University, Japan				*J Investig Dermatol Symp Proc* **4**: 105-109 (1999)	(478)
Grover R, 1999	Study done on a predominantly Black sample; acral lentiginous lesions only				*Br J Plast Surg* **52**: 122-126 (1999)	(479)
Ichikawa T, 1998	Study done on an Asian population from Shinshu University, Japan				*Br J Dermatol* **138**: 763-768 (1998)	(480)
Nagahama M, 1998	Study done on an Asian population from Kobe University, Japan				*Br J Dermatol* **138**: 981-985 (1998)	(481)
Chang TG, 1997	Study done on an Asian population from Taiwan, R.O.C.				*Biochem Biophys Res Commun* **230**: 85-88 (1997)	(482)
Kanoko M, 1996	Study done on an Asian population from Kobe University, Japan				*J Dermatol Sci* **12**: 97-103 (1996)	(483)

Supplemental Table 1: Summary of identified manuscripts (n=515), cont'd

First author, year	Assayed samples: nevi	1° melanomas	metastases	Proteins assayed	Citation	Ref.
Excluded studies: Non-Caucasian sample (n=30), cont'd						
Ohashi A, 1996	Study done on an Asian population from Kobe University, Japan				*Melanoma Res* **6**: 25-30 (1996)	(484)
Saitoh K, 1996	Study done on an Asian population from Sapporo Medical School, Japan				*Histopathology* **29**: 497-505 (1996)	(485)
Ueda M, 1994	Study done on an Asian population from Kobe University, Japan				*Br J Dermatol* **130**: 320-324 (1994)	(486)
Saitoh K, 1994	Study done on an Asian population from Sapporo Medical School, Japan				*J Pathol* **174**: 191-199 (1994)	(487)
Kageshita T, 1993	Study done on an Asian population from Kumamoto University, Japan				*Cancer Res* **53**: 4927-4932 (1993)	(488)
Kondoh M, 1993	Study done on an Asian population from Kobe University, Japan				*Melanoma Res* **3**: 241-245 (1993)	(489)
Yamamoto M, 1993	Study done on an Asian population from Sapporo Medical School, Japan				*Virchows Arch A Pathol Anat Histopathol* **422**: 127-131 (1993)	(490)
Hirano T, 1986	Study done on an Asian population from Nippon, Japan				*Acta Pathol Jpn* **36**: 733-743 (1986)	(491)
Excluded studies: Immunohistochemistry not performed (n=24)						
Webber BA, 2008	IHC not related to any progression or survival endpoints				*Appl Immunohistochem Mol Morphol* **16**: 19-23 (2008)	(492)
Nambiar S, 2007	Protein expression not assayed; RNA expression assessed by RTQ-PCR				*Carcinogenesis* **28**: 2501-2510 (2007)	(493)
Soikkeli J, 2007	Protein expression not assayed; RNA expression assessed by RTQ-PCR				*J Pathol* **213**: 180-189 (2007)	(494)
Winnepenninckx V, 2007	Although it appears as if new data are presented, any methods section is absent				*Expert Rev Anticancer Ther* **7**: 1611-1631 (2007)	(495)
Carvalho L, 2006	Telomerase activity assessed by PCR-ELISA-based TRAP assay				*J Plast Reconstr Aesthet Surg* **59**: 961-968 (2006)	(496)
Ellerhorst JA, 2006	Cell-based basic science research only				*Oncogene* **epub** (2006)	(497)
Korabiowska M, 2006	Protein expression not assayed; cDNA assessed for sequence variants				*Anticancer Res* **26**: 1231-1235 (2006)	(498)
Stabuc B, 2006	Protein expression levels determined by ELISA method only				*Neoplasma* **53**: 259-262 (2006)	(499)
Bales E, 2005	Protein expression levels assessed in tissues using Western blots				*Cancer Res* **65**: 629-697 (2005)	(500)
Thies A, 2004	Selected candidate was a glycolylation motif and not a protein				*J Pathol* **203**: 933-939 (2004)	(501)
Govindarajan B, 2003	IHC was performed on a single melanoma specimen				*J Biol Chem* **278**: 9790-9795 (2003)	(502)
Stabuc B, 2003	Protein expression levels determined by ELISA method only				*Oncol Rep* **10**: 635-639 (2003)	(503)
Chana JS, 2001	Protein expression levels assessed by dual-parameter flow cytometry				*Ann Plast Surg* **47**: 172-177 (2001)	(504)
Duncan LM, 2001	Protein expression not assayed; RNA levels measured by ISH				*J Clin Oncol* **19**: 568-576 (2001)	(505)
Scholl FA, 2001	Protein expression not assayed; RNA levels measured by ISH				*Cancer Res* **61**: 823-826 (2001)	(506)
Bartenjev I, 2000	Protein expression levels determined by ELISA method only				*Int J Dermatol* **39**: 599-602 (2000)	(507)
Rudolph P, 2000	Telomerase activity assessed by PCR-ELISA-based TRAP assay				*Am J Pathol* **156**: 1425-1432 (2000)	(508)
Nurnberg W, 1999	Protein expression not assayed; RNA levels measured by ISH				*J Pathol* **189**: 546-551 (1999)	(509)
Ross DA, 1998	Protein expression levels assessed by flow cytometry				*Br J Surg* **85**: 46-51 (1998)	(510)
Grover R, 1997	Protein expression levels assessed by flow cytometry				*Br J Plast Surg* **50**: 478-482 (1997)	(511)
Ross DA, 1997	Protein expression levels assessed by flow cytometry				*Br J Surg* **84**: 803-807 (1997)	(512)
Fleming MG, 1994	Protein levels not assessed; RNA levels measured by ISH				*Am J Dermatopathol* **16**: 383-391 (1994)	(513)
Walker MJ, 1991	Protein expression assessed by pharmacologic assay with radiolabeled ligand				*Cancer* **68**: 184-188 (1991)	(514)
Walker MJ, 1987	Protein expression assessed by pharmacologic assay with radiolabeled ligand				*J Clin Oncol* **5**: 1256-1261 (1987)	(515)

References

1. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer 2008;112(1):144-50.
2. Pearl RA, Pacifico MD, Richman PI, Wilson GD, Grover R. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. J Plast Reconstr Aesthet Surg 2008;61:265-271.
3. Vaisanen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol 2008;39:377-385.
4. Alonso SR, Tracey L, Ortiz P, Perez-Gomez B, Palacios J, Pollan M, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 2007;67(7):3450-60.
5. Piras F, Murtas D, Minerba L, Ugalde J, Floris C, Maxia C, et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology 2007;50(7):835-42.
6. Weinlich G, Topar G, Eisendle K, Fritsch PO, Zelger B. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma. J Eur Acad Dermatol Venereol 2007;21(5):669-77.
7. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 2006;119(4):861-6.
8. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. CD44v3 levels in primary cutaneous melanoma are predictive of prognosis: Assessment by the use of tissue microarray. Int J Cancer 2006;118(6):1460-4.
9. Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, et al. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol 2006;24(28):4565-9.
10. Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, Zelger B. Metallothionein - overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer 2006;94(6):835-41.
11. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, et al. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 2005;65(23):11185-92.
12. Pacifico MD, Grover R, Richman PI, Buffa F, Daley FM, Wilson GD. Identification of P-cadherin in primary melanoma using a tissue microarrayer: prognostic implications in a patient cohort with long-term follow up. Ann Plast Surg 2005;55(3):316-20.
13. Pacifico MD, Grover R, Richman PI, Buffa F, Daley FM, Wilson GD. nm23 as a prognostic marker in primary cutaneous melanoma: evaluation using tissue microarray in a patient group with long-term follow-up. Melanoma Res 2005;15(5):435-40.
14. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 2005;115(2):367-75.
15. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005;11(5):1835-41.
16. Soltani MH, Pichardo R, Song Z, Sangha N, Camacho F, Satyamoorthy K, et al. Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am J Pathol 2005;166(6):1841-50.

17. Straume O, Akslen LA. Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer 2005;93(8):933-8.
18. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004;164(1):193-203.
19. Berger AJ, Camp RL, Divito KA, Kluger HM, Halaban R, Rimm DL. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res 2004;64(23):8767-72.
20. Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res 2004;64(23):8773-7.
21. Hofbauer GF, Burkhart A, Schuler G, Dummer R, Burg G, Nestle FO. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother 2004;27(1):73-8.
22. Ilmonen S, Jahkola T, Turunen JP, Muhonen T, Asko-Seljavaara S. Tenascin-C in primary malignant melanoma of the skin. Histopathology 2004;45(4):405-11.
23. Li Q, Murphy M, Ross J, Sheehan C, Carlson JA. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol 2004;31(10):633-42.
24. Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003;63(23):8103-7.
25. Korabiowska M, Tscherny M, Stachura J, Berger H, Cordon-Cardo C, Brinck U. Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression. Mod Pathol 2002;15(4):426-33.
26. Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G, et al. Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer 2002;38(13):1708-16.
27. Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002;20(10):2530-6.
28. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 2001;195(5):530-6.
29. Ferrier CM, Suciu S, van Geloof WL, Straatman H, Eggermont AM, Koops HS, et al. High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 2000;83(10):1351-9.
30. Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000;6(9):3614-20.
31. Karjalainen JM, Tammi RH, Tammi MI, Eskelinen MJ, Agren UM, Parkkinen JJ, et al. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol 2000;157(3):957-65.
32. McDermott NC, Milburn C, Curran B, Kay EW, Barry Walsh C, Leader MB. Immunohistochemical expression of nm23 in primary invasive malignant melanoma is predictive of survival outcome. J Pathol 2000;190(2):157-62.
33. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000;6(5):1845-53.

34. Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchala A, Wasilewska A, et al. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 1999;70(3):150-60.
35. Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 1998;16(11):3584-91.
36. Tran TA, Ross JS, Carlson JA, Mihm MC, Jr. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum Pathol 1998;29(10):1085-90.
37. Vaisanen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998;186(1):51-8.
38. Potti A, Moazzam N, Tendulkar K, Javed NA, Koch M, Kargas S. Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. Anticancer Res 2003;23(5A):4023-6.
39. Potti A, Hille RC, Koch M. Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications. J Carcinog 2003;2(1):8.
40. Weinlich G, Bitterlich W, Mayr V, Fritsch PO, Zelger B. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients. Br J Dermatol 2003;149(3):535-41.
41. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997;74(5):535-9.
42. Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Collan Y, et al. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response. Oncology 2002;62(3):259-68.
43. Pearl RA, Pacifico MD, Richman PI, Stott DJ, Wilson GD, Grobbelaar AO. Ki-67 expression in melanoma. A potential method of risk assessment for the patient with a positive sentinel node. J Exp Clin Cancer Res 2007;26(1):109-15.
44. Mihic-Probst D, Mnich CD, Oberholzer PA, Seifert B, Sasse B, Moch H, et al. p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer 2006;118(9):2262-8.
45. Potti A, Moazzam N, Langness E, Sholes K, Tendulkar K, Koch M, et al. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol 2004;130(2):80-6. Epub 2003 Nov 21.
46. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003;13(5):493-501.
47. Maelandsmo GM, Holm R, Nesland JM, Fodstad O, Florenes VA. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 2003;9(9):3383-8.
48. Mu XC, Tran TA, Ross JS, Carlson JA. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma. J Cutan Pathol 2000;27(5):242-8.
49. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 1999;85(2):375-82.
50. Karjalainen JM, Eskelinen MJ, Kellokoski JK, Reinikainen M, Alhava EM, Kosma VM. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br J Cancer 1999;79(5-6):895-902.

51. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer 1999;85(11):2391-9.
52. Talve LA, Collan YU, Ekfors TO. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. J Cutan Pathol 1996;23(4):335-43.
53. Talve L, Kainu J, Collan Y, Ekfors T. Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. Pathol Res Pract 1996;192(8):825-33.
54. Ramsay JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995;105(1):22-6.
55. McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, et al. HSP90 as a marker of progression in melanoma. Ann Oncol 2008;19:590-4.
56. Jorgensen K, Davidson B, Florenes VA. Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma. Mod Pathol 2006;19(11):1446-55.
57. Lu F, Dai DL, Martinka M, Ho V, Li G. Nuclear ING2 expression is reduced in human cutaneous melanomas. Br J Cancer 2006;95(1):80-6. Epub 2006 Jun 6.
58. McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, et al. Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006;12(12):3856-63.
59. Sirigu P, Piras F, Minerba L, Murtas D, Maxia C, Colombari R, et al. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: a comparison of two populations from different geographical regions. Eur J Histochem 2006;50(3):191-8.
60. Slipicevic A, Holm R, Nguyen MT, Bohler PJ, Davidson B, Florenes VA. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol 2005;124(4):528-36.
61. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 2005;58(11):1163-9.
62. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 2004;17(8):990-7.
63. Bachmann IM, Straume O, Akslen LA. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol 2004;25(6):1559-65.
64. Dai DL, Martinka M, Bush JA, Li G. Reduced Apaf-1 expression in human cutaneous melanomas. Br J Cancer 2004;91(6):1089-95.
65. Florenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B. Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am J Clin Pathol 2004;122(3):412-20.
66. Korabiowska M, Schlott T, Siems N, Muller A, Cordon-Cardo C, Fischer G, et al. Analysis of adenomatous polyposis coli gene expression, APC locus-microsatellite instability and APC promoter methylation in the progression of melanocytic tumours. Mod Pathol 2004;17(12):1539-44.
67. Torlakovic EE, Bilalovic N, Nesland JM, Torlakovic G, Florenes VA. Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis. Mod Pathol 2004;17(11):1400-6.
68. Cruz J, Reis-Filho JS, Silva P, Lopes JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003;65(1):72-82.

69. Jorgensen K, Holm R, Maelandsmo GM, Florenes VA. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res 2003;9(14):5325-31.
70. Korabiowska M, Cordon-Cardo C, Betke H, Schlott T, Kotthaus M, Stachura J, et al. GADD153 is an independent prognostic factor in melanoma: immunohistochemical and molecular genetic analysis. Histol Histopathol 2002;17(3):805-11.
71. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002;97(4):432-8.
72. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2002;160(3):1009-19.
73. Straume O, Akslen LA. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001;159(1):223-35.
74. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000;6(12):4768-75.
75. Henrique R, Azevedo R, Bento MJ, Domingues JC, Silva C, Jeronimo C. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. J Am Acad Dermatol 2000;43(6):991-1000.
76. Dai DL, Wang Y, Liu M, Martinka M, Li G. Bim Expression Is Reduced in Human Cutaneous Melanomas. J Invest Dermatol 2008;128:403-7.
77. Tucci MG, Lucarini G, Brancorsini D, Zizzi A, Pugnaloni A, Giacchetti A, et al. Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 2007;157(6):1212-6.
78. Wang Y, Dai DL, Martinka M, Li G. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin Cancer Res 2007;13(14):4111-6.
79. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24(2):268-73. Epub 2005 Dec 5.
80. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006;94(12):1879-86. Epub 2006 May 23.
81. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 2005;11(24 Pt 1):8606-14.
82. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 2005;23(7):1473-82.
83. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005;23(31):8048-56.
84. Ilmonen S, Hernberg M, Pyrhonen S, Tarkkanen J, Asko-Seljavaara S. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res 2005;15(5):375-81.
85. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O. Ezrin in primary cutaneous melanoma. Mod Pathol 2005;18(4):503-10.
86. Karst AM, Dai DL, Martinka M, Li G. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 2005;24(6):1111-6.

87. Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G, et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005;36(7):724-31.
88. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005;124(5):1044-52.
89. Korabiowska M, Fischer G, Steinacker A, Stachura J, Cordon-Cardo C, Brinck U. Cytokeratin positivity in paraffin-embedded malignant melanomas: comparative study of KL1, A4 and Lu5 antibodies. Anticancer Res 2004;24(5B):3203-7.
90. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J, Pyrhonen S. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res 2004;14(1):29-37.
91. Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, et al. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 2003;9(12):4409-14.
92. Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL, et al. Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 2003;103(5):652-6.
93. Gutman M, Even-Sapir E, Merimsky O, Trejo L, Klausner JM, Lev-Chelouche D. The role of interleukin-8 in the initiation and progression of human cutaneous melanoma. Anticancer Res 2002;22(6A):3395-8.
94. Hazan C, Melzer K, Panageas KS, Li E, Kamino H, Kopf A, et al. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer 2002;95(3):634-40.
95. Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 2002;94(23):1803-6.
96. Korabiowska M, Ruschenburg I, Betke H, Stachura J, Schlott T, Cardo CC, et al. Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma. Pathobiology 2001;69(5):274-80.
97. Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol 2001;44(2):188-92.
98. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol 2001;145(2):203-9.
99. Ricaniadis N, Kataki A, Agnantis N, Androulakis G, Karakousis CP. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol 2001;27(1):88-93.
100. Korabiowska M, Brinck U, Dengler H, Stachura J, Schauer A, Droese M. Analysis of the DNA mismatch repair proteins expression in malignant melanomas. Anticancer Res 2000;20(6B):4499-505.
101. Sauroja I, Smeds J, Vlaykova T, Kumar R, Talve L, Hahka-Kemppinen M, et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000;28(4):404-14.
102. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988;48(4):1019-25.
103. Fearfield LA, Larkin JM, Rowe A, A'Hern R, Fisher C, Francis N, et al. Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma. Br J Dermatol 2007;156(3):440-7.

104. Bauer R, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, et al. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays. J Clin Pathol 2006;59(7):699-705. Epub 2006 Mar 24.
105. Demirkesen C, Buyukpinarbasili N, Ramazanoglu R, Oguz O, Mandel NM, Kaner G. The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor. Pathology 2006;38(2):132-7.
106. Fecker LF, Geilen CC, Tchernev G, Trefzer U, Assaf C, Kurbanov BM, et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 2006;126(6):1366-71.
107. Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, et al. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol 2006;33(4):280-5.
108. Kashani-Sabet M, Shaikh L, Miller JR, 3rd, Nosrati M, Ferreira CM, Debs RJ, et al. NF-kappa B in the vascular progression of melanoma. J Clin Oncol 2004;22(4):617-23.
109. Sarris M, Scolyer RA, Konopka M, Thompson JF, Harper CG, Lee CS. Cytoplasmic expression of nm23 predicts the potential for cerebral metastasis in patients with primary cutaneous melanoma. Melanoma Res 2004;14(1):23-7.
110. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999;30(3):339-44.
111. Otto FJ, Goldmann T, Biess B, Lippold A, Suter L, Westhoff U. Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters. Oncology 1999;56(3):208-14.
112. Hernberg M, Turunen JP, von Boguslawsky K, Muhonen T, Pyrhonen S. Prognostic value of biomarkers in malignant melanoma. Melanoma Res 1998;8(3):283-91.
113. Sparrow LE, English DR, Taran JM, Heenan PJ. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol 1998;20(1):12-6.
114. Holmes SC, MacKie RM. The value of Nm23 expression as an independent prognostic indicator in primary thick melanoma. J Cutan Pathol 1996;23(4):344-9.
115. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Kim DK, Das Gupta TK. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases. Surgery 1995;118(4):669-73; discussion 673-5.
116. Reddy VB, Gattuso P, Aranha G, Carson HJ. Cell proliferation markers in predicting metastases in malignant melanoma. J Cutan Pathol 1995;22(3):248-51.
117. Sparrow LE, English DR, Heenan PJ, Dawkins HJ, Taran J. Prognostic significance of p53 over-expression in thin melanomas. Melanoma Res 1995;5(6):387-92.
118. Kernohan NM, Rankin R. S-100 protein: a prognostic indicator in cutaneous malignant melanoma? Histopathology 1987;11(12):1285-93.
119. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR Is Activated in the Majority of Malignant Melanomas. J Invest Dermatol 2008;128:980-7.
120. Batinac T, Hadzisejdic I, Brumini G, Ruzic A, Vojnikovic B, Zamolo G. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions. Coll Antropol 2007;31 Suppl 1:17-22.
121. Bertucci F, Pages C, Finetti P, Rochaix P, Lamant L, Devilard E, et al. Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers. Anticancer Res 2007;27(5A):3441-9.

122. Chwirot BW, Kuzbicki L. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Res 2007;17(3):139-45.
123. Demirkan NC, Kesen Z, Akdag B, Larue L, Delmas V. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions. Clin Exp Dermatol 2007;32(6):733-9.
124. Denicourt C, Saenz CC, Datnow B, Cui XS, Dowdy SF. Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res 2007;67(19):9238-43.
125. Denk AE, Bettstetter M, Wild PJ, Hoek K, Bataille F, Dietmaier W, et al. Loss of maspin expression contributes to a more invasive potential in malignant melanoma. Pigment Cell Res 2007;20(2):112-9.
126. Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel-Lewandrowski C, et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 2007;110(11):2519-27.
127. Ferrari D, Lombardi M, Ricci R, Michiara M, Santini M, De Panfilis G. Dermatopathological indicators of poor melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma. J Cutan Pathol 2007;34(9):705-12.
128. Giehl KA, Nagele U, Volkenandt M, Berking C. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma. J Cutan Pathol 2007;34(1):7-14.
129. Gilaberte Y, Vera J, Coscojuela C, Roca MJ, Parrado C, Gonzalez S. [Expression of galanin in melanocytic tumors]. Actas Dermosifiliogr 2007;98(1):24-34.
130. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007;20(1):102-7.
131. Lebe B, Pabuccuoglu U, Ozer E. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions. Appl Immunohistochem Mol Morphol 2007;15(2):160-4.
132. Leotlela PD, Wade MS, Duray PH, Rhode MJ, Brown HF, Rosenthal DT, et al. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 2007;26(26):3846-56.
133. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol 2007;34(8):597-600.
134. Neto DS, Pantaleao L, de Sa BC, Landman G. Alpha-v-beta3 integrin expression in melanocytic nevi and cutaneous melanoma. J Cutan Pathol 2007;34(11):851-6.
135. Pecina-Slaus N, Zigmund M, Kusec V, Martic TN, Cacic M, Slaus M. E-cadherin and beta-catenin expression patterns in malignant melanoma assessed by image analysis. J Cutan Pathol 2007;34(3):239-46.
136. Pisacane AM, Picciotto F, Risio M. CD31 and CD34 expression as immunohistochemical markers of endothelial transdifferentiation in human cutaneous melanoma. Cell Oncol 2007;29(1):59-66.
137. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007;96(12):1879-87.
138. Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A, Rigby H, et al. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer 2007;97(2):223-30.
139. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007;13(7):2246-53.

140. Rakosy Z, Vizkeleti L, Ecsedi S, Voko Z, Begany A, Barok M, et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 2007;121(8):1729-37.
141. Rothhammer T, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, et al. Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. Cancer Biomark 2007;3(2):111-7.
142. Sanki A, Li W, Colman M, Karim RZ, Thompson JF, Scolyer RA. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology 2007;39(6):551-7.
143. Seidl H, Richtig E, Tilz H, Stefan M, Schmidbauer U, Asslaber M, et al. Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol 2007;38(5):768-80.
144. Singh RS, Diwan AH, Zhang PS, Prieto VG. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions. J Cutan Pathol 2007;34(3):220-5.
145. Thies A, Berlin A, Brunner G, Schulze HJ, Moll I, Pfuller U, et al. Glycoconjugate profiling of primary melanoma and its sentinel node and distant metastases: implications for diagnosis and pathophysiology of metastases. Cancer Lett 2007;248(1):68-80.
146. Weishaupt C, Munoz KN, Buzney E, Kupper TS, Fuhlbrigge RC. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 2007;13(9):2549-56.
147. Wilsher M, Cheerala B. WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections. Histopathology 2007;51(5):605-10.
148. Zygouris P, Tsiambas E, Tiniakos D, Karameris A, Athanassiou AE, Kittas C, et al. Evaluation of combined h-TERT, bcl-2, and caspases 3 and 8 expression in cutaneous malignant melanoma based on tissue microarrays and computerized image analysis. J Buon 2007;12(4):513-9.
149. Arndt S, Bosserhoff AK. TANGO is a tumor suppressor of malignant melanoma. Int J Cancer 2006;119(12):2812-20.
150. Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006;12(3 Pt 1):764-71.
151. Ding Y, Prieto VG, Zhang PS, Rosenthal S, Smith KJ, Skelton HG, et al. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer 2006;106(5):1123-9.
152. Honig A, Rieger L, Kapp M, Krockenberger M, Eck M, Dietl J, et al. Increased tartrate-resistant acid phosphatase (TRAP) expression in malignant breast, ovarian and melanoma tissue: an investigational study. BMC Cancer 2006;6(199):199.
153. Kaariainen E, Nummela P, Soikkeli J, Yin M, Lukk M, Jahkola T, et al. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. J Pathol 2006;210(2):181-91.
154. Kalogeraki A, Garbagnati F, Darivianaki K, Delides GS, Santinami M, Stathopoulos EN, et al. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes. Anticancer Res 2006;26(5A):3551-4.
155. Kuphal S, Wallner S, Schimanski CC, Bataille F, Hofer P, Strand S, et al. Expression of Hugl-1 is strongly reduced in malignant melanoma. Oncogene 2006;25(1):103-10.
156. Kuphal S, Lodermeyer S, Bataille F, Schuierer M, Hoang BH, Bosserhoff AK. Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene 2006;25(36):5027-36. Epub 2006 Mar 27.
157. Kuzbicki L, Gajo B, Chwirot BW. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res 2006;16(3):235-43.
158. Kuzbicki L, Sarnecka A, Chwirot BW. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 2006;16(1):29-36.

159. Kuzbicki L, Aladowicz E, Chwirot BW. Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions. Melanoma Res 2006;16(5):435-44.
160. Massi D, Tarantini F, Franchi A, Paglierani M, Di Serio C, Pellerito S, et al. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol 2006;19(2):246-54.
161. Miracco C, De Nisi MC, Arcuri F, Cosci E, Pacenti L, Toscano M, et al. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours. Int J Oncol 2006;28(2):345-52.
162. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 2006;126(10):2272-80. Epub 2006 Jun 1.
163. Niedojadlo K, Labedzka K, Lada E, Milewska A, Chwirot BW. Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi. Pigment Cell Res 2006;19(1):43-50.
164. Packer L, Pavey S, Parker A, Stark M, Johansson P, Clarke B, et al. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis 2006;27(9):1778-86.
165. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, et al. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 2006;12(22):6709-15.
166. Scala S, Giuliano P, Ascierto PA, Ierano C, Franco R, Napolitano M, et al. Human melanoma metastases express functional CXCR4. Clin Cancer Res 2006;12(8):2427-33.
167. Schmidt AN, Nanney LB, Boyd AS, King LE, Jr., Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol 2006;15(12):971-80.
168. Shannan B, Seifert M, Leskov K, Boothman D, Pfohler C, Tilgen W, et al. Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. Anticancer Res 2006;26(4A):2707-16.
169. Simonetti O, Goteri G, Lucarini G, Filosa A, Pieramici T, Rubini C, et al. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur J Cancer 2006;42(8):1181-7. Epub 2006 Apr 27.
170. Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, Wheaton WW, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 2006;12(8):925-32. Epub 2006 Jul 30.
171. Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006;125(2):209-16.
172. Vereecken P, Reynaert S, Lalmand MC, Zouaoui-Boudjeltia K, Heenen M, Van Den Heule B, et al. Decreased immunoreactive maspin expression in intermediate thickness and thick primary melanoma lesions. J Int Med Res 2006;34(1):52-7.
173. Winnepenninckx V, Debiec-Rychter M, Belien JA, Fiten P, Michiels S, Lazar V, et al. Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. Mod Pathol 2006;19(9):1170-80. Epub 2006 Jun 23.
174. Xi Y, Nakajima G, Hamil T, Fodstad O, Riker A, Ju J. Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Mol Cancer Ther 2006;5(12):3078-84.
175. Zhang H, Rosdahl I. Bcl-xL and bcl-2 proteins in melanoma progression and UVB-induced apoptosis. Int J Oncol 2006;28(3):661-6.
176. Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 2006;168(5):1666-75.

177. Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005;65(9):3937-41.
178. Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, et al. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res 2005;11(9):3175-83.
179. Brychtova S, Fiuraskova M, Brychta T, Hirnak J. [The role of intermedial filament nestin in malignant melanoma progression]. Cesk Patol 2005;41(4):143-5.
180. Busam KJ, Kucukgol D, Sato E, Frosina D, Teruya-Feldstein J, Jungbluth AA. Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers. Am J Surg Pathol 2005;29(3):400-6.
181. Cohn ML, Goncharuk VN, Diwan AH, Zhang PS, Shen SS, Prieto VG. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. J Cutan Pathol 2005;32(8):533-6.
182. Ehrmann J, Kolar Z, Mokry J. Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J Clin Pathol 2005;58(2):222-3.
183. Fiuraskova M, Brychtova S, Sedlakova E, Benes P, Zalesak B, Hlobilkova A, et al. Molecular changes in PDEGF and bFGF in malignant melanomas in relation to the stromal microenvironment. Anticancer Res 2005;25(6B):4299-303.
184. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, et al. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 2005;65(21):9851-60.
185. Kuivanen T, Ahokas K, Virolainen S, Jahkola T, Holtta E, Saksela O, et al. MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype. Virchows Arch 2005;447(6):954-60. Epub 2005 Aug 20.
186. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005;166(3):823-30.
187. Longo-Imedio MI, Longo N, Trevino I, Lazaro P, Sanchez-Mateos P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 2005;117(5):861-5.
188. Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M, et al. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 2005;36(6):676-85.
189. Murry BP, Greiter-Wilke A, Paulsen DP, Hiatt KM, Beltrami CA, Marchetti D. Selective heparanase localization in malignant melanoma. Int J Oncol 2005;26(2):345-52.
190. Pisacane AM, Risio M. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res 2005;15(1):39-43.
191. Quatresooz P, Pierard GE. Immunohistochemical investigation of alpha1 (IV) and alpha5 (IV) collagen chains in a broad spectrum of melanocytic tumours. Melanoma Res 2005;15(3):161-8.
192. Ramirez JA, Guitart J, Rao MS, Diaz LK. Cyclin D1 expression in melanocytic lesions of the skin. Ann Diagn Pathol 2005;9(4):185-8.
193. Redondo P, Lloret P, Idoate M, Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 2005;30(5):541-5.
194. Roesch A, Becker B, Meyer S, Wild P, Hafner C, Landthaler M, et al. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol 2005;18(9):1249-57.
195. Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005;65(2):448-56.

196. Sedghizadeh PP, Williams JD, Allen CM, Prasad ML. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium. Med Sci Monit 2005;11(7):BR189-94.
197. Varney ML, Johansson SL, Singh RK. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 2005;15(5):417-25.
198. Vereecken P, Debray C, Petein M, Awada A, Lalmand MC, Laporte M, et al. Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch Dermatol Res 2005;296(8):353-8. Epub 2005 Jan 11.
199. Vetter CS, Muller-Blech K, Schrama D, Brocker EB, Becker JC. Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch Dermatol Res 2005;297(1):26-30. Epub 2005 May 19.
200. Woenckhaus C, Maile S, Uffmann S, Bansemir M, Dittberner T, Poetsch M, et al. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol Histopathol 2005;20(2):501-8.
201. Zhang H. Survivin protein in UVB induced apoptosis of melanoma cells and in melanoma progression. Oncol Rep 2005;13(6):1121-6.
202. Baldi A, Santini D, Russo P, Catricala C, Amantea A, Picardo M, et al. Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 2004;13(2):93-7.
203. Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, Stolz W, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 2004;13(1):27-32.
204. Bilalovic N, Sandstad B, Golouh R, Nesland JM, Selak I, Torlakovic EE. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol 2004;17(10):1251-8.
205. Dissemond J, Busch M, Kothen T, Mors J, Weimann TK, Lindeke A, et al. Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. Cancer Lett 2004;203(2):225-31.
206. Ellerhorst JA, Naderi AA, Johnson MK, Pelletier P, Prieto VG, Diwan AH, et al. Expression of thyrotropin-releasing hormone by human melanoma and nevi. Clin Cancer Res 2004;10(16):5531-6.
207. Hazarika P, McCarty MF, Prieto VG, George S, Babu D, Koul D, et al. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res 2004;64(20):7361-9.
208. Ivan D, Diwan AH, Esteva FJ, Prieto VG. Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions. Mod Pathol 2004;17(7):811-8.
209. Kang SH, Fung MA, Gandour-Edwards R, Reilly D, Dizon T, Grahn J, et al. Heat shock protein 27 is expressed in normal and malignant human melanocytes in vivo. J Cutan Pathol 2004;31(10):665-71.
210. Kluger HM, DiVito K, Berger AJ, Halaban R, Ariyan S, Camp RL, et al. Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res 2004;14(3):207-10.
211. Krengel S, Groteluschen F, Bartsch S, Tronnier M. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression. J Cutan Pathol 2004;31(1):1-7.
212. Li Z, Metze D, Nashan D, Muller-Tidow C, Serve HL, Poremba C, et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 2004;123(4):737-45.

213. McNulty SE, del Rosario R, Cen D, Meyskens FL, Jr., Yang S. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res 2004;17(2):173-80.
214. Ng KC, Campos EI, Martinka M, Li G. XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol 2004;123(6):1127-34.
215. Poyraz A, Akyurek N, Gonul, II, Erdem O. P21 and Bax expression in cutaneous malignant melanomas: correlation with histologic prognostic parameters. J Exp Clin Cancer Res 2004;23(4):625-31.
216. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004;64(15):5186-92.
217. Stefanou D, Batistatou A, Zioga A, Arkoumani E, Papachristou DJ, Agnantis NJ. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions. Int J Surg Pathol 2004;12(2):133-8.
218. Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, et al. Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 2004;23(12):2264-74.
219. Woenckhaus C, Fenic I, Giebel J, Hauser S, Failing K, Woenckhaus J, et al. Loss of heterozygosity at 12p13 and loss of p27KIP1 protein expression contribute to melanoma progression. Virchows Arch 2004;445(5):491-7.
220. Banfalvi T, Udvarhelyi N, Orosz Z, Gergye M, Gilde K, Timar J. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels. Oncology 2003;64(4):374-9.
221. Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, et al. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 2003;163(2):683-90.
222. Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003;63(20):6716-25.
223. Dissemond J, Kothen T, Mors J, Weimann TK, Lindeke A, Goos M, et al. Downregulation of tapasin expression in progressive human malignant melanoma. Arch Dermatol Res 2003;295(2):43-9.
224. Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, et al. Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther 2003;2(1):9-17.
225. Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, et al. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett 2003;189(2):237-47.
226. Goulet AC, Einsphar JG, Alberts DS, Beas A, Burk C, Bhattacharyya A, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003;2(6):713-8.
227. Hafner C, Bataille F, Meyer S, Becker B, Roesch A, Landthaler M, et al. Loss of EphB6 expression in metastatic melanoma. Int J Oncol 2003;23(6):1553-9.
228. Haritopoulos KN, Lazaris AC, Kavantzas N, Tseleni-Balafouta S, Thomopoulou G, Aroni K. ICAM-1 and beta(3) integrin immunoexpression in malignant melanoma cells: can they be used as additional predictors? APMIS 2003;111(3):421-9.
229. Keehn CA, Smoller BR, Morgan MB. Expression of the ets-1 proto-oncogene in melanocytic lesions. Mod Pathol 2003;16(8):772-7.

230. Miranda E, Vizoso F, Martin A, Quintela I, Corte MD, Segui ME, et al. Apolipoprotein D expression in cutaneous malignant melanoma. J Surg Oncol 2003;83(2):99-105.
231. Potti A, Hille R, Koch M. Immunohistochemical determination of HER-2/neu in malignant melanoma. Anticancer Res 2003;23(5A):4067-9.
232. Redondo P, Sanchez-Carpintero I, Bauza A, Idoate M, Solano T, Mihm MC, Jr. Immunologic escape and angiogenesis in human malignant melanoma. J Am Acad Dermatol 2003;49(2):255-63.
233. Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R, et al. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 2003;39(5):666-74.
234. Rosenwald IB, Wang S, Savas L, Woda B, Pullman J. Expression of translation initiation factor eIF-2alpha is increased in benign and malignant melanocytic and colonic epithelial neoplasms. Cancer 2003;98(5):1080-8.
235. Sander CS, Hamm F, Elsner P, Thiele JJ. Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br J Dermatol 2003;148(5):913-22.
236. Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 2003;30(9):539-47.
237. Slater M, Scolyer RA, Gidley-Baird A, Thompson JF, Barden JA. Increased expression of apoptotic markers in melanoma. Melanoma Res 2003;13(2):137-45.
238. Sundram U, Harvell JD, Rouse RV, Natkunam Y. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol 2003;16(8):802-10.
239. Wang H, Shen SS, Wang H, Diwan AH, Zhang W, Fuller GN, et al. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions. J Cutan Pathol 2003;30(10):599-605.
240. Xu X, Tahan SR, Pasha TL, Zhang PJ. Expression of neurotrophin receptor Trk-C in nevi and melanomas. J Cutan Pathol 2003;30(5):318-22.
241. Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, et al. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 2002;21(43):6684-8.
242. Demunter A, Libbrecht L, Degreef H, De Wolf-Peeters C, van den Oord JJ. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod Pathol 2002;15(4):454-61.
243. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002;62(24):7335-42.
244. Dobrowolski R, Hein R, Buettner R, Bosserhoff AK. Loss of p14ARF expression in melanoma. Arch Dermatol Res 2002;293(11):545-51.
245. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, et al. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol 2002;20(4):1069-74.
246. Goncharuk VN, Ross JS, Carlson JA. Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol 2002;29(7):430-8.
247. Kanitakis J, Narvaez D, Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 2002;12(3):241-4.
248. Kim SH, Gunnery S, Choe JK, Mathews MB. Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 2002;21(57):8741-8.

249. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002;29(6):354-8.
250. Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol 2002;197(2):179-87.
251. Nouman GS, Anderson JJ, Mathers ME, Leonard N, Crosier S, Lunec J, et al. Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions. Histopathology 2002;40(4):360-6.
252. Pavey SJ, Cummings MC, Whiteman DC, Castellano M, Walsh MD, Gabrielli BG, et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 2002;12(6):539-47.
253. Redondo P, Solano T, B VA, Bauza A, Idoate M. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma. Br J Dermatol 2002;147(1):80-6.
254. Simonetti O, Lucarini G, Brancorsini D, Nita P, Bernardini ML, Biagini G, et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 2002;95(9):1963-70.
255. Timar J, Raso E, Dome B, Ladanyi A, Banfalvi T, Gilde K, et al. Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. Clin Exp Metastasis 2002;19(3):225-32.
256. Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002;160(2):549-57.
257. Winer I, Normolle DP, Shureiqi I, Sondak VK, Johnson T, Su L, et al. Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis. Melanoma Res 2002;12(5):429-34.
258. Ahrens T, Assmann V, Fieber C, Termeer C, Herrlich P, Hofmann M, et al. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J Invest Dermatol 2001;116(1):93-101.
259. Baldi A, Santini D, Battista T, Dragonetti E, Ferranti G, Petitti T, et al. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. J Cell Biochem 2001;83(3):364-72.
260. Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE. Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interactions in invasion and metastasis. In Vivo 2001;15(1):57-64.
261. de Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Brocker EB, Renard N, et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 2001;193(1):13-20.
262. Demunter A, De Wolf-Peeters C, Degreef H, Stas M, van den Oord JJ. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 2001;438(5):485-91.
263. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001;61(1):303-8.
264. Fang D, Hallman J, Sangha N, Kute TE, Hammarback JA, White WL, et al. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma. Am J Pathol 2001;158(6):2107-15.
265. Fink-Puches R, Pilarski P, Schmidbauer U, Kerl H, Soyer HP. No evidence for c-erbB-2 overexpression in cutaneous melanoma. Anticancer Res 2001;21(4A):2793-5.

266. Frahm SO, Schubert C, Parwaresch R, Rudolph P. High proliferative activity may predict early metastasis of thin melanomas. Hum Pathol 2001;32(12):1376-81.
267. Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 2001;54(3):229-35.
268. Gilhooly EM, Morse-Gaudio M, Bianchi L, Reinhart L, Rose DP, Connolly JM, et al. Loss of expression of protein kinase C beta is a common phenomenon in human malignant melanoma: a result of transformation or differentiation? Melanoma Res 2001;11(4):355-69.
269. Hussein MR, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, Sudilovsky O. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas. Am J Dermatopathol 2001;23(4):308-14.
270. Innominato PF, Libbrecht L, van den Oord JJ. Expression of neurotrophins and their receptors in pigment cell lesions of the skin. J Pathol 2001;194(1):95-100.
271. King R, Googe PB, Weilbaecher KN, Mihm MC, Jr., Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 2001;25(1):51-7.
272. Loggini B, Rinaldi I, Pingitore R, Cristofani R, Castagna M, Barachini P. Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance. Tumori 2001;87(3):179-86.
273. Massi D, Franchi A, Sardi I, Magnelli L, Paglierani M, Borgognoni L, et al. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 2001;194(2):194-200.
274. Polsky D, Young AZ, Busam KJ, Alani RM. The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas. Cancer Res 2001;61(16):6008-11.
275. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001;61(20):7642-6.
276. Quintela I, Vizoso F, Serra C, Gonzalez LO, Fernandez R, Merino AM, et al. Immunohistochemical study of pepsinogen C expression in cutaneous malignant melanoma: association with clinicopathological parameters. Int J Biol Markers 2001;16(4):240-4.
277. Ahmed B, Van Den Oord JJ. Expression of the inducible isoform of nitric oxide synthase in pigment cell lesions of the skin. Br J Dermatol 2000;142(3):432-40.
278. Aroni K, Charitopoulos KN, Lazaris AC, Davaris P. Lack of vasopressin expression in malignant melanomas. Melanoma Res 2000;10(6):535.
279. Bergman R, Azzam H, Sprecher E, Manov L, Munichor M, Friedman-Birnbaum R, et al. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. J Am Acad Dermatol 2000;42(3):496-500.
280. Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 2000;13(4):459-65.
281. Hofmann UB, Westphal JR, Waas ET, Becker JC, Ruiter DJ, van Muijen GN. Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol 2000;115(4):625-32.
282. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000;191(3):245-56.
283. Kanter-Lewensohn L, Dricu A, Girnita L, Wejde J, Larsson O. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of

IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors 2000;17(3):193-202.
284. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 2000;292(5):225-32.
285. Persons DL, Arber DA, Sosman JA, Borelli KA, Slovak ML. Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma. Anticancer Res 2000;20(3B):1965-8.
286. van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 2000;156(3):769-74.
287. Ahmed B, Van Den Oord JJ. Expression of the neuronal isoform of nitric oxide synthase (nNOS) and its inhibitor, protein inhibitor of nNOS, in pigment cell lesions of the skin. Br J Dermatol 1999;141(1):12-9.
288. Bayer-Garner IB, Hough AJ, Jr., Smoller BR. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. Mod Pathol 1999;12(8):770-4.
289. Birck A, Kirkin AF, Zeuthen J, Hou-Jensen K. Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res 1999;9(4):375-81.
290. Boni R, Wellmann A, Man YG, Hofbauer G, Brinkmann U. Expression of the proliferation and apoptosis-associated CAS protein in benign and malignant cutaneous melanocytic lesions. Am J Dermatopathol 1999;21(2):125-8.
291. Chiodino C, Cesinaro AM, Ottani D, Fantini F, Giannetti A, Trentini GP, et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 1999;113(3):415-8.
292. Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999;84(5):494-501.
293. Goldmann T, Suter L, Ribbert D, Otto F. The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predicts metastasis. Pathol Res Pract 1999;195(3):171-5.
294. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113(6):1076-81.
295. Hartmann A, Kunz M, Kostlin S, Gillitzer R, Toksoy A, Brocker EB, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999;59(7):1578-83.
296. Korabiowska M, Brinck U, Ruschenburg I, Schlott T, Droese M, Stachura J. Bcl2 and Bax expression in naevi and melanomas and their relation to ploidy status and proliferation. Pol J Pathol 1999;50(1):17-21.
297. Lowney JK, Boucher LD, Swanson PE, Doherty GM. Interferon regulatory factor-1 and -2 expression in human melanoma specimens. Ann Surg Oncol 1999;6(6):604-8.
298. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, et al. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 1999;84(2):160-8.
299. Ozer E, Sagol O, Kuyucuoglu F. Ki-67 immunostaining and stereologic estimation of nuclear volume in melanocytic skin tumors. Anal Quant Cytol Histol 1999;21(1):42-6.
300. Reed JA, Finnerty B, Albino AP. Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression. Am J Pathol 1999;155(2):549-55.
301. Sanders DS, Blessing K, Hassan GA, Bruton R, Marsden JR, Jankowski J. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. Mol Pathol 1999;52(3):151-7.

302. Singh RK, Varney ML, Bucana CD, Johansson SL. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 1999;9(4):383-7.
303. Sparrow LE, Heenan PJ. Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas J Dermatol 1999;40(1):19-24.
304. Tschugguel W, Pustelnik T, Lass H, Mildner M, Weninger W, Schneeberger C, et al. Inducible nitric oxide synthase (iNOS) expression may predict distant metastasis in human melanoma. Br J Cancer 1999;79(9-10):1609-12.
305. Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry Dt, Schuchter L, et al. Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 1999;30(5):562-7.
306. Vlaykova T, Laurila P, Muhonen T, Hahka-Kemppinen M, Jekunen A, Alitalo K, et al. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 1999;9(1):59-68.
307. Zhang XD, Hersey P. Expression of catenins and p120cas in melanocytic nevi and cutaneous melanoma: deficient alpha-catenin expression is associated with melanoma progression. Pathology 1999;31(3):239-46.
308. Bergman R, Kerner H, Manov L, Friedman-Birnbaum R. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas. Am J Dermatopathol 1998;20(3):262-5.
309. Betke H, Korabiowska M, Brinck U, Trybus-Galuszka H, Kellner S, Okon K, et al. The role of nm23 in melanoma progression and its prognostic significance. Pol J Pathol 1998;49(2):93-6.
310. Busam KJ, Chen YT, Old LJ, Stockert E, Iversen K, Coplan KA, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 1998;22(8):976-82.
311. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75(4):517-24.
312. Goldmann T, Ribbert D, Suter L, Brode M, Otto F. Tumor characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics. J Exp Clin Cancer Res 1998;17(4):483-9.
313. Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev 1998;22(3):185-94.
314. Hensley C, Spitzler S, McAlpine BE, Lynn M, Ansel JC, Solomon AR, et al. In vivo human melanoma cytokine production: inverse correlation of GM-CSF production with tumor depth. Exp Dermatol 1998;7(6):335-41.
315. Hofbauer GF, Kamarashev J, Geertsen R, Boni R, Dummer R. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol 1998;25(4):204-9.
316. Hofbauer GF, Kamarashev J, Geertsen R, Boni R, Dummer R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res 1998;8(4):337-43.
317. Keller-Melchior R, Schmidt R, Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 1998;110(6):932-8.
318. Khare VK, Albino AP, Reed JA. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. J Cutan Pathol 1998;25(1):2-10.
319. Silye R, Karayiannakis AJ, Syrigos KN, Poole S, van Noorden S, Batchelor W, et al. E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 1998;186(4):350-5.

320. Sparrow LE, Eldon MJ, English DR, Heenan PJ. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998;20(3):255-61.
321. Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G, et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998;4(8):1865-71.
322. Van den Oord JJ. Expression of CD26/dipeptidyl-peptidase IV in benign and malignant pigment-cell lesions of the skin. Br J Dermatol 1998;138(4):615-21.
323. Boni R, Heizmann CW, Doguoglu A, Ilg EC, Schafer BW, Dummer R, et al. Ca(2+)-binding proteins S100A6 and S100B in primary cutaneous melanoma. J Cutan Pathol 1997;24(2):76-80.
324. de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997;57(15):3223-9.
325. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 1997;7 Suppl 2(2):S19-26.
326. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997;71(2):142-7.
327. Korabiowska M, Betke H, Kellner S, Stachura J, Schauer A. Differential expression of growth arrest, DNA damage genes and tumour suppressor gene p53 in naevi and malignant melanomas. Anticancer Res 1997;17(5A):3697-700.
328. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997;108(2):210-4.
329. Marcoval J, Moreno A, Graells J, Vidal A, Escriba JM, Garcia-Ramirez M, et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 1997;24(4):212-8.
330. Montone KT, van Belle P, Elenitsas R, Elder DE. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997;10(9):939-44.
331. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, et al. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 1997;7(4):313-21.
332. Nicotra MR, Nistico P, Mangoni A, Di Filippo F, Marincola FM, Natali PG. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas. J Immunother (1997) 1997;20(6):466-9.
333. Reichrath J, Seyfried P, Braun R, Muller SM, Baum HP, Bahmer FA. Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin. Dermatology 1997;194(2):136-9.
334. Rudolph P, Schubert C, Schubert B, Parwaresch R. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J Am Acad Dermatol 1997;37(2 Pt 1):169-78.
335. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997;76(7):930-4.
336. Seelentag WK, Boni R, Gunthert U, Futo E, Burg G, Heitz PU, et al. Expression of CD44 isoforms and beta 1,6-branched oligosaccharides in human malignant melanoma is correlated with tumor progression but not with metastatic potential. J Cutan Pathol 1997;24(4):206-11.
337. Trotter MJ, Tang L, Tron VA. Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol 1997;24(5):265-71.
338. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997;151(3):665-70.

339. Weiss J, Biwer B, Schliz M, Jung EG. Clinicopathological and prognostic relevance of Rap1-GAP expression in melanocytic tumors. Arch Dermatol Res 1997;289(10):573-7.
340. Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, et al. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 1996;74(1):33-42.
341. Danen EH, de Vries TJ, Morandini R, Ghanem GG, Ruiter DJ, van Muijen GN. E-cadherin expression in human melanoma. Melanoma Res 1996;6(2):127-31.
342. De Vries TJ, De Wit PE, Clemmensen I, Verspaget HW, Weidle UH, Brocker EB, et al. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions. J Pathol 1996;179(3):260-5.
343. de Vries TJ, Verheijen JH, de Bart AC, Weidle UH, Ruiter DJ, van Muijen GN. Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression. Cancer Res 1996;56(6):1432-9.
344. Easty DJ, Maung K, Lascu I, Veron M, Fallowfield ME, Hart IR, et al. Expression of NM23 in human melanoma progression and metastasis. Br J Cancer 1996;74(1):109-14.
345. Francia G, Mitchell SD, Moss SE, Hanby AM, Marshall JF, Hart IR. Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Cancer Res 1996;56(17):3855-8.
346. Harwood CA, Green MA, Cook MG. CD44 expression in melanocytic lesions: a marker of malignant progression? Br J Dermatol 1996;135(6):876-82.
347. Lee CS, Pirdas A, Lee MW. Immunohistochemical demonstration of the nm23-H1 gene product in human malignant melanoma and Spitz nevi. Pathology 1996;28(3):220-4.
348. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 1996;19(3):192-205.
349. Reed JA, McNutt NS, Bogdany JK, Albino AP. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression. J Cutan Pathol 1996;23(6):495-505.
350. Simon JC, Heider KH, Dietrich A, Wuttig C, Schopf E, Adolf GR, et al. Expression of CD44 isoforms in human skin cancer. Eur J Cancer 1996;32A(8):1394-400.
351. Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 1996;148(6):1887-94.
352. Xerri L, Battyani Z, Grob JJ, Parc P, Hassoun J, Bonerandi JJ, et al. Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res 1996;6(3):223-30.
353. Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, et al. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer 1995;61(4):548-56.
354. Cerroni L, Soyer HP, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995;17(1):7-11.
355. Chetty R, Cerroni L, Pulford K, Giatromanolaki A, Biddolph S, Kaklamanis L, et al. TAL1 gene deletions and TAL1 protein expression in sporadic melanoma. Melanoma Res 1995;5(4):251-4.
356. Danen EH, Jansen KF, Van Kraats AA, Cornelissen IM, Ruiter DJ, Van Muijen GN. Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int J Cancer 1995;61(4):491-6.
357. Gelsleichter L, Gown AM, Zarbo RJ, Wang E, Coltrera MD. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995;8(5):530-5.

358. Korabiowska M, Brinck U, Mirecka J, Kellner S, Marx D, Schauer A. Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions. In Vivo 1995;9(5):433-8.
359. Lee CS, Pirdas A, Lee MW. p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis. Australas J Dermatol 1995;36(4):192-5.
360. Mirecka J, Korabiowska M, Schauer A. Comparative distribution of S-100 protein and antigen HMB-45 in various types of melanomas and naevi. Pol J Pathol 1995;46(3):167-72.
361. Natali PG, Nicotra MR, Di Filippo F, Bigotti A. Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions. Br J Cancer 1995;71(6):1243-7.
362. Platz A, Ringborg U, Grafstrom E, Hoog A, Lagerlof B. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res 1995;5(2):101-6.
363. Podhajcer OL, Bover L, Bravo AI, Ledda MF, Kairiyama C, Calb I, et al. Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi. J Invest Dermatol 1995;104(3):340-4.
364. Poremba C, Yandell DW, Metze D, Kamanabrou D, Bocker W, Dockhorn-Dworniczak B. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 1995;7(7-8):331-9.
365. Ramsay JA, From L, Kahn HJ. bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995;8(2):150-4.
366. Reed JA, Loganzo F, Jr., Shea CR, Walker GJ, Flores JF, Glendening JM, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55(13):2713-8.
367. Rudolph P, Lappe T, Schubert C, Schmidt D, Parwaresch RM, Christophers E. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol 1995;147(6):1615-25.
368. Schadendorf D, Jurgovsky K, Kohlmus CM, Czarnetzki BM. Glutathione and related enzymes in tumor progression and metastases of human melanoma. J Invest Dermatol 1995;105(1):109-12.
369. Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995;5(2):93-100.
370. Weiss J, Heine M, Korner B, Pilch H, Jung EG. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 1995;133(1):23-31.
371. Danen EH, Ten Berge PJ, Van Muijen GN, Van 't Hof-Grootenboer AE, Brocker EB, Ruiter DJ. Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 1994;24(3):249-56.
372. de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994;144(1):70-81.
373. Saenz-Santamaria MC, Reed JA, McNutt NS, Shea CR. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol 1994;21(5):393-7.
374. Si Z, Hersey P. Immunohistological examination of the relationship between metastatic potential and expression of adhesion molecules and 'selectins' on melanoma cells. Pathology 1994;26(1):6-15.
375. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994;145(2):294-300.
376. von Schoultz E, Carlstrom K, Henriksson R, Lagerlof B, Hansson J. Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res 1994;4(6):401-5.

377. Bishop PW, Menasce LP, Yates AJ, Win NA, Banerjee SS. An immunophenotypic survey of malignant melanomas. Histopathology 1993;23(2):159-66.
378. Carrel S, Zografos L, Schreyer M, Rimoldi D. Expression of CALLA/CD10 on human melanoma cells. Melanoma Res 1993;3(5):319-23.
379. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993;53(10 Suppl):2235-8.
380. McGregor JM, Yu CC, Dublin EA, Barnes DM, Levison DA, MacDonald DM. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993;128(6):606-11.
381. Natali PG, Nicotra MR, Di Renzo MF, Prat M, Bigotti A, Cavaliere R, et al. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 1993;68(4):746-50.
382. Rieger E, Hofmann-Wellenhof R, Soyer HP, Kofler R, Cerroni L, Smolle J, et al. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study. J Cutan Pathol 1993;20(3):229-36.
383. Schadendorf D, Gawlik C, Haney U, Ostmeier H, Suter L, Czarnetzki BM. Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol 1993;170(4):429-34.
384. Vacca A, Ribatti D, Roncali L, Lospalluti M, Serio G, Carrel S, et al. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer 1993;72(2):455-61.
385. de Wit PE, Moretti S, Koenders PG, Weterman MA, van Muijen GN, Gianotti B, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 1992;99(2):168-73.
386. Denton KJ, Stretch JR, Gatter KC, Harris AL. A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol 1992;167(2):187-91.
387. Jonjic N, Martin-Padura I, Pollicino T, Bernasconi S, Jilek P, Bigotti A, et al. Regulated expression of vascular cell adhesion molecule-1 in human malignant melanoma. Am J Pathol 1992;141(6):1323-30.
388. Natali PG, Nicotra MR, Cavaliere R, Giannarelli D, Bigotti A. Tumor progression in human malignant melanoma is associated with changes in alpha 6/beta 1 laminin receptor. Int J Cancer 1991;49(2):168-72.
389. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res 1991;51(21):5976-9.
390. Takahashi H, Strutton GM, Parsons PG. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody. Histopathology 1991;18(3):221-7.
391. Wollina U, Kilian U, Henkel U, Schaarschmidt H, Knopf B. The initial steps of tumor progression in melanocytic lineage: a histochemical approach. Anticancer Res 1991;11(4):1405-14.
392. Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 1990;66(4):765-71.
393. Cohen C, DeRose PB, Campbell WG, Schlosnagle DC, Sgoutas D. Estrogen receptor status in malignant melanoma. Am J Dermatopathol 1990;12(6):562-4.
394. Natali P, Nicotra MR, Cavaliere R, Bigotti A, Romano G, Temponi M, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990;50(4):1271-8.

395. van Muijen GN, Ruiter DJ, Hoefakker S, Johnson JP. Monoclonal antibody PAL-M1 recognizes the transferrin receptor and is a progression marker in melanocytic lesions. J Invest Dermatol 1990;95(1):65-9.
396. Zarbo RJ, Gown AM, Nagle RB, Visscher DW, Crissman JD. Anomalous cytokeratin expression in malignant melanoma: one- and two-dimensional western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol 1990;3(4):494-501.
397. Johnson JP, Stade BG, Holzmann B, Schwable W, Riethmuller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A 1989;86(2):641-4.
398. Kaudewitz P, Braun-Falco O, Ernst M, Landthaler M, Stolz W, Gerdes J. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading. Am J Pathol 1989;134(5):1063-8.
399. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study. Am J Dermatopathol 1989;11(4):301-7.
400. Natali PG, Roberts JT, Difilippo F, Bigotti A, Dent PB, Ferrone S, et al. Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance. Cancer 1987;59(1):55-63.
401. Hagen EC, Vennegoor C, Schlingemann RO, van der Velde EA, Ruiter DJ. Correlation of histopathological characteristics with staining patterns in human melanoma assessed by (monoclonal) antibodies reactive on paraffin sections. Histopathology 1986;10(7):689-700.
402. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C, et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 1984;44(9):3930-5.
403. Chakravarti N, Lotan R, Diwan AH, Warneke CL, Johnson MM, Prieto VG. Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin Cancer Res 2007;13(16):4817-24.
404. Mihic-Probst D, Kuster A, Kilgus S, Bode-Lesniewska B, Ingold-Heppner B, Leung C, et al. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer 2007;121(8):1764-70.
405. Mnich CD, Hoek KS, Oberholzer PA, Seifert B, Hafner J, Dummer R, et al. Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness. Melanoma Res 2007;17(2):131-6.
406. Tchernev G, Orfanos CE. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J Cutan Pathol 2007;34(3):247-56.
407. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O'Neill D, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immun 2007;7(11):11.
408. Velazquez EF, Yancovitz M, Pavlick A, Berman R, Shapiro R, Bogunovic D, et al. Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. J Transl Med 2007;5(2):2.
409. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007;20(4):416-26.
410. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors. J Clin Pathol 2007;60(6):596-9.
411. Tang L, Dai DL, Su M, Martinka M, Li G, Zhou Y. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 2006;12(12):3716-22.

412. Wild PJ, Meyer S, Bataille F, Woenckhaus M, Ameres M, Vogt T, et al. Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors. Arch Dermatol 2006;142(4):471-6.
413. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 2006;37(10):1286-94.
414. Corte MD, Gonzalez LO, Corte MG, Quintela I, Pidal I, Bongera M, et al. Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma. Int J Biol Markers 2005;20(4):242-8.
415. Roesch A, Becker B, Meyer S, Hafner C, Wild PJ, Landthaler M, et al. Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma. Mod Pathol 2005;18(4):565-72.
416. Wu H, Barusevicius A, Babb J, Klein-Szanto A, Godwin A, Elenitsas R, et al. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol 2005;32(2):125-30.
417. Bron LP, Scolyer RA, Thompson JF, Hersey P. Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology 2004;36(6):561-5.
418. Forster-Horvath C, Dome B, Paku S, Ladanyi A, Somlai B, Jalkanen S, et al. Loss of vascular adhesion protein-1 expression in intratumoral microvessels of human skin melanoma. Melanoma Res 2004;14(2):135-40.
419. Innocenzi D, Alo PL, Balzani A, Sebastiani V, Silipo V, La Torre G, et al. Fatty acid synthase expression in melanoma. J Cutan Pathol 2003;30(1):23-8.
420. Jonjic N, Zamolo G, Stifter S, Fuckar D, Gruber F, Sasso F, et al. Cytomorphological variations, proliferation and angiogenesis in the prognosis of cutaneous melanoma. Clin Exp Dermatol 2003;28(3):310-4.
421. Woenckhaus C, Giebel J, Failing K, Fenic I, Dittberner T, Poetsch M. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? J Pathol 2003;201(2):278-87.
422. Brinck U, Ruschenburg I, Di Como CJ, Buschmann N, Betke H, Stachura J, et al. Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas. Int J Mol Med 2002;10(6):707-11.
423. Dawn G, MacKie RM. Expression of endoglin in human melanocytic lesions. Clin Exp Dermatol 2002;27(2):153-6.
424. Eliopoulos P, Mohammed MQ, Henry K, Retsas S. Overexpression of HER-2 in thick melanoma. Melanoma Res 2002;12(2):139-45.
425. Middleman BR, Friedman M, Lawson DH, DeRose PB, Cohen C. Melanoma growth stimulatory activity in primary malignant melanoma: prognostic significance. Mod Pathol 2002;15(5):532-7.
426. Berset M, Cerottini JP, Guggisberg D, Romero P, Burri F, Rimoldi D, et al. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer 2001;95(1):73-7.
427. Kamarashev J, Ferrone S, Seifert B, Boni R, Nestle FO, Burg G, et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 2001;95(1):23-8.
428. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res 2001;11(2):157-66.

429. Korabiowska M, Brinck U, Middel P, Brinkmann U, Berger H, Radzun HJ, et al. Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance. Anticancer Res 2000;20(3A):1781-5.
430. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, Das Gupta TK. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000;60(18):5012-6.
431. Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R. Prognostic value of pololike kinase expression in melanomas. JAMA 2000;283(4):479-80.
432. Vihinen P, Nikkola J, Vlaykova T, Hahka-Kemppinen M, Talve L, Heino J, et al. Prognostic value of beta1 integrin expression in metastatic melanoma. Melanoma Res 2000;10(3):243-51.
433. Ciotti P, Pesce GP, Cafiero F, Rainero ML, Sementa A, Nicolo G, et al. Intercellular adhesion molecule-1 (ICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) co-expression in cutaneous malignant melanoma lesions. Melanoma Res 1999;9(3):253-60.
434. Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Franssila K, et al. MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma. Oncology 1999;57(3):242-52.
435. Boni R, Bantschapp O, Muller B, Burg G. c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma. Dermatology 1998;196(3):288-91.
436. Essner R, Kuo CT, Wang H, Wen DR, Turner RR, Nguyen T, et al. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 1998;82(2):309-16.
437. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998;153(1):305-12.
438. Healy E, Belgaid C, Takata M, Harrison D, Zhu NW, Burd DA, et al. Prognostic significance of allelic losses in primary melanoma. Oncogene 1998;16(17):2213-8.
439. Konstadoulakis MM, Vezeridis M, Hatziyianni E, Karakousis CP, Cole B, Bland KI, et al. Molecular oncogene markers and their significance in cutaneous malignant melanoma. Ann Surg Oncol 1998;5(3):253-60.
440. Bjornhagen V, Lindholm J, Auer G. Analysis of nuclear DNA and morphometry, and proliferating cell nuclear antigen in primary and metastatic malignant melanoma. Scand J Plast Reconstr Surg Hand Surg 1997;31(2):109-18.
441. Dietrich A, Tanczos E, Vanscheidt W, Schopf E, Simon JC. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer 1997;33(6):926-30.
442. Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, et al. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997;57(8):1554-60.
443. van den Oord JJ, Maes A, Stas M, Nuyts J, De Wever I, De Wolf-Peeters C. Prognostic significance of nm23 protein expression in malignant melanoma. An immunohistochemical study. Melanoma Res 1997;7(2):121-8.
444. Vielkind JR, Huhn K, Tron VA. The Xiphophorus-derived antibody, XMEL, shows sensitivity and specificity for human cutaneous melanoma but is not a prognostic marker. J Cutan Pathol 1997;24(10):620-7.
445. Boni R, Doguoglu A, Burg G, Muller B, Dummer R. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996;35(3 Pt 1):416-8.
446. Hieken TJ, Farolan M, Ronan SG, Shilkaitis A, Wild L, Das Gupta TK. Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 1996;63(1):169-73.

447. Maelandsmo GM, Holm R, Fodstad O, Kerbel RS, Florenes VA. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol 1996;149(6):1813-22.
448. van den Oord JJ, Maes A, Stas M, Nuyts J, Battocchio S, Kasran A, et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 1996;149(6):1953-61.
449. Lazaris AC, Theodoropoulos GE, Aroni K, Saetta A, Davaris PS. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 1995;426(5):461-7.
450. Schadendorf D, Heidel J, Gawlik C, Suter L, Czarnetzki BM. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 1995;87(5):366-71.
451. Casazza S, Gambini C, Tunesi G, Rovida S, Caruso F, Pastorino A, et al. [Expression of P53 protein in cutaneous melanoma]. Pathologica 1993;85(1097):335-42.
452. Woosley JT, Dietrich DR. Prognostic significance of PCNA grade in malignant melanoma. J Cutan Pathol 1993;20(6):498-503.
453. Zelger B, Hittmair A, Schir M, Ofner C, Ofner D, Fritsch PO, et al. Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology 1993;23(3):257-63.
454. Soyer HP. Ki 67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters. J Cutan Pathol 1991;18(4):264-72.
455. Natali PG, Nicotra MR, Nuti M, Bigotti G, Calabro A, Schlom J, et al. Molecular profile, tissue distribution and prognostic evaluation of a human melanoma-carcinoma antigen recognized by the murine monoclonal antibody B1.1. Int J Biol Markers 1988;3(4):211-20.
456. Pocza P, Suli-Vargha H, Darvas Z, Falus A. Locally generated VGVAPG and VAPG elastin-derived peptides amplify melanoma invasion via the galectin-3 receptor. Int J Cancer 2008;122(9):1972-1980.
457. Brezillon S, Venteo L, Ramont L, D'Onofrio MF, Perreau C, Pluot M, et al. Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin Exp Dermatol 2007;32(4):405-16.
458. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 2006;37(8):1000-8. Epub 2006 Jun 21.
459. Straume O, Akslen LA. Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. Angiogenesis 2003;6(4):295-301.
460. Hussein MR, Sun M, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, et al. Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog 2002;34(1):35-44.
461. Van Duinen CM, Fleuren GJ, Bruijn JA. The extracellular matrix in pigmented skin lesions: an immunohistochemical study. Histopathology 1994;24(1):33-40.
462. Tao J, Li Y, Liu YQ, Li L, Liu J, Shen X, et al. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors. Br J Dermatol 2008;158(1):88-94.
463. Kawasaki K, Kawakami T, Watabe H, Itoh F, Mizoguchi M, Soma Y. Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma. Br J Dermatol 2007;156(4):613-9.
464. Liao YH, Hsu SM, Huang PH. ARMS depletion facilitates UV irradiation induced apoptotic cell death in melanoma. Cancer Res 2007;67(24):11547-56.

465. Wu Y, Zhang XB, Liu HJ, Zheng LD, Li JW, Lin Y. [Expression of neutral endopeptidase and motility-related protein-1 in cutaneous malignant melanoma]. Zhonghua Bing Li Xue Za Zhi 2007;36(7):466-9.
466. Nishimura K, Hirokawa YS, Mizutani H, Shiraishi T. Reduced heterochromatin protein 1-beta (HP1beta) expression is correlated with increased invasive activity in human melanoma cells. Anticancer Res 2006;26(6B):4349-56.
467. Mustika R, Budiyanto A, Nishigori C, Ichihashi M, Ueda M. Decreased expression of Apaf-1 with progression of melanoma. Pigment Cell Res 2005;18(1):59-62.
468. Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, et al. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer 2005;103(8):1693-700.
469. Kageshita T, Ishihara T, Tokuo H, Funasaka Y, Ichihashi M, Dong J, et al. Widespread expression of parathyroid hormone-related peptide in melanocytic cells. Br J Dermatol 2003;148(3):533-8.
470. Koganehira Y, Takeoka M, Ehara T, Sasaki K, Murata H, Saida T, et al. Reduced expression of actin-binding proteins, h-caldesmon and calponin h1, in the vascular smooth muscle inside melanoma lesions: an adverse prognostic factor for malignant melanoma. Br J Dermatol 2003;148(5):971-80.
471. Sato H, Nagashima Y, Chrousos GP, Ichihashi M, Funasak Y. The expression of corticotropin-releasing hormone in melanoma. Pigment Cell Res 2002;15(2):98-103.
472. Shukuwa T, Katayama I, Koji T. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. Mod Pathol 2002;15(4):387-96.
473. Kageshita T, Kawakami Y, Ono T. Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients. J Dermatol Sci 2001;25(1):36-44.
474. Kageshita T, Funasaka Y, Ichihashi M, Wakamatsu K, Ito S, Ono T. Tissue factor expression and serum level in patients with melanoma does not correlate with disease progression. Pigment Cell Res 2001;14(3):195-200.
475. Sugita K, Yamamoto O, Asahi M. Immunohistochemical analysis of metallothionein expression in malignant melanoma in Japanese patients. Am J Dermatopathol 2001;23(1):29-35.
476. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother 2000;49(6):314-8.
477. Torisu-Itakura H, Furue M, Kuwano M, Ono M. Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas. Jpn J Cancer Res 2000;91(9):906-10.
478. Funasaka Y, Sato H, Chakraborty AK, Ohashi A, Chrousos GP, Ichihashi M. Expression of proopiomelanocortin, corticotropin-releasing hormone (CRH), and CRH receptor in melanoma cells, nevus cells, and normal human melanocytes. J Investig Dermatol Symp Proc 1999;4(2):105-9.
479. Grover R, Chana J, Grobbelaar AO, Hudson DA, Forder M, Wilson GD, et al. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma. Br J Plast Surg 1999;52(2):122-6.
480. Ichikawa T, Masumoto J, Kaneko M, Saida T, Sagara J, Taniguchi S. Moesin and CD44 expression in cutaneous melanocytic tumours. Br J Dermatol 1998;138(5):763-8.
481. Nagahama M, Funasaka Y, Fernandez-Frez ML, Ohashi A, Chakraborty AK, Ueda M, et al. Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br J Dermatol 1998;138(6):981-5.

482. Chang TG, Wang J, Chen LW, Hsu CY, Chang HW, Chen JS, et al. Loss of expression of the p16 gene is frequent in malignant skin tumors. Biochem Biophys Res Commun 1997;230(1):85-8.
483. Kanoko M, Ueda M, Nagano T, Ichihashi M. Expression of p53 protein in melanoma progression. J Dermatol Sci 1996;12(2):97-103.
484. Ohashi A, Funasaka Y, Ueda M, Ichihashi M. c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi. Melanoma Res 1996;6(1):25-30.
485. Saitoh K, Takahashi H, Yamamoto M, Kishi H, Parsons PG. Expression of metastasis suppressor gene product, nm23 protein, is not inversely correlated with the tumour progression in human malignant melanomas. Histopathology 1996;29(6):497-505.
486. Ueda M, Funasaka Y, Ichihashi M, Mishima Y. Stable and strong expression of basic fibroblast growth factor in naevus cell naevus contrasts with aberrant expression in melanoma. Br J Dermatol 1994;130(3):320-4.
487. Saitoh K, Takahashi H, Sawada N, Parsons PG. Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin. J Pathol 1994;174(3):191-9.
488. Kageshita T, Yoshii A, Kimura T, Kuriya N, Ono T, Tsujisaki M, et al. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 1993;53(20):4927-32.
489. Kondoh M, Ueda M, Ichihashi M, Mishima Y. Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas. Melanoma Res 1993;3(4):241-5.
490. Yamamoto M, Takahashi H. Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin. Virchows Arch A Pathol Anat Histopathol 1993;422(2):127-32.
491. Hirano T. Immunohistochemical study of malignant melanoma. Acta Pathol Jpn 1986;36(5):733-43.
492. Webber BA, Lawson D, Cohen C. Maspin and Mutant p53 Expression in Malignant Melanoma and Carcinoma: Use of Tissue Microarray. Appl Immunohistochem Mol Morphol 2008;16(1):19-23.
493. Nambiar S, Mirmohammadsadegh A, Hassan M, Mota R, Marini A, Alaoui A, et al. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance. Carcinogenesis 2007;28(12):2501-10.
494. Soikkeli J, Lukk M, Nummela P, Virolainen S, Jahkola T, Katainen R, et al. Systematic search for the best gene expression markers for melanoma micrometastasis detection. J Pathol 2007;213(2):180-9.
495. Winnepenninckx V, van den Oord JJ. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors. Expert Rev Anticancer Ther 2007;7(11):1611-31.
496. Carvalho L, Lipay M, Belfort F, Santos I, Andrade J, Haddad A, et al. Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg 2006;59(9):961-8.
497. Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 2006;25(28):3956-62. Epub 2006 Feb 13.
498. Korabiowska M, Brinck U, Stachura J, Jawien J, Hasse FM, Cordon-Cardos C, et al. Exonic deletions of mismatch repair genes MLH1 and MSH2 correlate with prognosis and protein expression levels in malignant melanomas. Anticancer Res 2006;26(2A):1231-5.
499. Stabuc B, Mrevlje Z, Markovic J, Stabuc-Silih M. Expression and prognostic significance of Cathepsin L in early cutaneous malignant melanoma. Neoplasma 2006;53(3):259-62.
500. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, et al. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 2005;65(3):692-7.

501. Thies A, Schachner M, Berger J, Moll I, Schulze HJ, Brunner G, et al. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma. J Pathol 2004;203(4):933-9.
502. Govindarajan B, Bai X, Cohen C, Zhong H, Kilroy S, Louis G, et al. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 2003;278(11):9790-5.
503. Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Oncol Rep 2003;10(3):635-9.
504. Chana JS, Grover R, Wilson GD, Hudson DA, Forders M, Sanders R, et al. The prognostic importance of c-myc oncogene expression in head and neck melanoma. Ann Plast Surg 2001;47(2):172-7.
505. Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 2001;19(2):568-76.
506. Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R, Schafer BW. PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 2001;61(3):823-6.
507. Bartenjev I, Rudolf Z, Stabuc B, Vrhovec I, Perkovic T, Kansky A. Cathepsin D expression in early cutaneous malignant melanoma. Int J Dermatol 2000;39(8):599-602.
508. Rudolph P, Schubert C, Tamm S, Heidorn K, Hauschild A, Michalska I, et al. Telomerase activity in melanocytic lesions: A potential marker of tumor biology. Am J Pathol 2000;156(4):1425-32.
509. Nurnberg W, Tobias D, Otto F, Henz BM, Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 1999;189(4):546-51.
510. Ross DA, Wilson GD. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br J Surg 1998;85(1):46-51.
511. Grover R, Ross DA, Wilson GD, Sanders R. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma. Br J Plast Surg 1997;50(7):478-82.
512. Ross DA, Wilson GD. Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma. Br J Surg 1997;84(6):803-7.
513. Fleming MG, Howe SF, Graf LH, Jr. Expression of insulin-like growth factor I (IGF-I) in nevi and melanomas. Am J Dermatopathol 1994;16(4):383-91.
514. Walker MJ, Ronan SG, Han MC, Beattie CW, Das Gupta TK. Interrelationship between histopathologic characteristics of melanoma and estrogen receptor status. Cancer 1991;68(1):184-8.
515. Walker MJ, Beattie CW, Patel MK, Ronan SM, Das Gupta TK. Estrogen receptor in malignant melanoma. J Clin Oncol 1987;5(8):1256-61.